Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome

Administering a non-selective mGluR activator like fasoracetam to ADHD patients with genetic alterations in mGluR network genes provides an effective treatment for ADHD symptoms and comorbid conditions, improving clinical and rating scale scores.

JP2024164036AInactive Publication Date: 2024-11-26THE CHILDRENS HOSPITAL OF PHILADELPHIA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024125021
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2015-09-08
Filing Date
2024-07-31
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for ADHD, particularly in patients with genetic alterations in metabotropic glutamate receptor (mGluR) network genes, are inadequate due to side effects and short active half-lives of existing drugs, and there is a need for personalized treatment approaches based on genetic profiles.

Method used

Administering a non-selective metabotropic glutamate receptor (mGluR) activator, such as fasoracetam, to subjects with genetic alterations in mGluR network genes, tailored to individual genetic profiles, potentially combined with other medications or therapies.

Benefits of technology

The method effectively reduces ADHD symptoms, including inattention, hyperactivity, and impulsivity, with significant improvements observed in Clinical Global Impression and ADHD Rating Scale scores, and can address comorbid conditions like ODD and anxiety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164036000018
    Figure 2024164036000018
  • Figure 2024164036000019
    Figure 2024164036000019
  • Figure 2024164036000020
    Figure 2024164036000020
Patent Text Reader

Abstract

To provide medicines for treating attention deficit hyperactivity disorder (ADHD), 22q deletion and / or duplication syndrome, and comorbidities, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.SOLUTION: The present invention provides a medicine for treating attention deficit hyperactivity disorder (ADHD) in a subject, comprising a therapeutically effective amount of fasoracetam.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority to four U.S. provisional patent applications, including U.S. Provisional Patent Applications Nos. 62 / 215628, 62 / 215633, 62 / 215636, and 62 / 215673, each filed on September 8, 2015, each of which is incorporated herein by reference in its entirety.

[0002] This application relates to treating attention deficit hyperactivity disorder (ADHD) and 22q syndrome, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene with non-selective activators of metabotropic glutamate receptors. [Background technology]

[0003] Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that can cause significant disability during childhood and later in life. Symptoms of ADHD include inattention, hyperactivity, and impulsivity.

[0004] The inventors previously conducted a large-scale genome-wide study comparing copy number variations (CNVs) in about 3500 ADHD cases compared to about 13,000 controls, and found that CNVs in genes encoding metabotropic glutamate receptors (mGluR proteins or GRM genes) and CNVs in genes encoding proteins that interact with mGluRs were significantly more frequent in ADHD cases compared to controls. (See WO 2012 / 027491 and U.S. Patent Application Publication No. 2013 / 0203814; Elia et al., Nature Genetics, 44(1):78-84 (2012)). The frequency of each individual genetic alteration appears to be quite low. However, overall, about 11% or more of ADHD cases have at least one genetic alteration in a gene encoding an mGluR network protein compared to about 1% of controls. Thus, ADHD patients are about 10 times more likely than control individuals to have a genetic alteration affecting one or more mGluR network genes. Furthermore, a network analysis of the mGluR pathway in approximately 1000 cases and 4000 controls in a European-American population revealed that copy number variations (CNVs) in genes encoding proteins involved in the mGluR signaling pathway and their interacting proteins affect approximately 20% of ADHD cases compared to controls.

[0005] There is no cure for ADHD, but symptoms can be managed with a combination of behavioral and pharmacotherapy. Currently approved treatments for AHDH include several neurostimulants and non-psychostimulants. Current medications, especially stimulants, are not ideal because they have many potentially harmful side effects and short active half-lives. Moreover, stimulants are often misused and abused by eligible and unqualified patients alike. Therefore, additional ADHD medications are needed. In addition, given the genetic heterogeneity of ADHD patients, ADHD treatment may be improved by tailoring a reliable pharmacotherapy scheme to each patient based on their underlying genetic profile.

[0006] The inventors conducted a clinical trial testing a nonselective activator of mGluR proteins, also called NFC-1 or fasoracetam monohydrate, in pediatric ADHD patients with at least one genetic alteration in a gene encoding an mGluR network gene.

[0007] The trial also included ADHD patients with 22q syndrome, characterized by a deletion or duplication in the 22q11.2 region of chromosome 22. These syndromes occur in at least about 1 in 2,000-4,000 children and can involve the disruption of as many as 30-40 genes. Genes that may be affected include RANBP1, an mGluR network gene. Children with deletions or duplications in 22q11.2 have higher than average rates of psychiatric disorders, including ADHD, autism spectrum disorder (ASD), and anxiety disorders, and a significant proportion may develop psychosis, such as schizophrenia, later in life. Children with deletions or duplications in the region may also suffer from a variety of intellectual disabilities.

[0008] Treatment of psychiatric symptoms in 22q syndrome patients can be complicated due to the physical abnormalities of these patients, including cardiac anomalies.For example, it may be necessary to avoid the use of neurostimulants that are widely prescribed elsewhere due to negative side effects in the 22q syndrome population.Therefore, improved therapeutic treatments are needed, especially for patients with ADHD, ASD, anxiety disorders, or other conditions who have an underlying 22q genetic syndrome. Summary of the Invention

[0009] Provided herein are methods for treating attention deficit hyperactivity disorder (ADHD) in a subject, the methods comprising administering to the subject a therapeutically effective amount of a nonselective metabotropic glutamate receptor (mGluR) activator, thereby treating ADHD.

[0010] Also provided is a method of treating attention deficit hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a nonselective metabotropic glutamate receptor (mGluR) activator to a subject having at least one genetic alteration in an mGluR network gene, thereby treating ADHD.

[0011] Further provided herein is a method of treating ADHD in a subject, comprising administering a non-selective mGluR activator to a subject having ADHD in an amount or dosing regimen proven effective to obtain a Clinical Global Impression-Improvement (CGI-I) score of 1 or 2 after at least 4 weeks of treatment in a majority of subjects in at least one clinical trial, and / or an improvement of at least 25%, e.g., at least 30%, at least 35%, or at least 40% in ADHD rating scale score after at least 4 weeks of treatment.

[0012] In some embodiments, the subject has a genetic alteration in at least one mGluR network gene. In some embodiments, the subject has a genetic alteration in at least two mGluR network genes.

[0013] In some embodiments, the subject is a child or adolescent subject, e.g., a subject between the ages of 5 and 17, between 8 and 17, between 5 and 12, between 5 and 8, between 8 and 12, between 12 and 18, between 13 and 18, or between 12 and 17. In other embodiments, the subject is an adult.

[0014] In some embodiments, the non-selective mGluR activator is fasoracetam, for example, fasoracetam monohydrate (NFC-1).

[0015] In some embodiments where the activator is fasoracetam, fasoracetam is administered at a dose of 50-400 mg, e.g., 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, administered once, twice or three times daily. In some embodiments, fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg or 400 mg twice daily, e.g., 100-200 mg twice daily.

[0016] In some embodiments of the above methods of treating ADHD, the activator is in combination with a stimulant, e.g., methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, or lisdexamfetamine, and / or in combination with a non-stimulant, e.g., atomoxetine, clonidine, or guanfacine, and / or in combination with an antidepressant, e.g., fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, or monoamine oxidase inhibitors, and / or in combination with an anti-anxiety drug, e.g., barbiturates, pregabalin, or benzodiazepines. in combination with azepam (including chlordiazepoxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam or midazolam), and / or in combination with antipsychotics, e.g., aripiprazole, It is administered in combination with ramazole or risperidone, and / or in combination with a beta-blocker, such as acebutolol, atenolol, betaxolol, bisoprolol, esmolol, nebivolol, metoprolol, cartelol, penbutolol, pindolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, propranolol, sotalol, or timolol.

[0017] In some embodiments, the activator is administered in combination with a non-pharmacological therapy, for example, brain stimulation, for example, vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetoconvulsive therapy, and / or deep brain stimulation.

[0018] In some embodiments, the ADHD subject has at least one comorbid phenotype or condition, such as oppositional defiant disorder (ODD), anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder. In some embodiments, the ADHD subject has 22q deletion or duplication syndrome. In some embodiments, the subject does not have at least one of ODD, anxiety disorder, conduct disorder, Tourette's syndrome, autism, 22q deletion or duplication syndrome, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder, or does not have any of them. In some embodiments, the subject has ODD. In some embodiments, the method treats ODD in the subject, for example, by reducing symptoms of argumentativeness and defiance, vindictiveness, and / or anger and irritability. In some embodiments, the ADHD subject has a comorbid phenotype, such as a mood disorder or a sleep disorder, such as insomnia. In some embodiments, the method treats the mood or sleep disorder, for example, by reducing the symptoms thereof. In some embodiments, the subject has a comorbid condition, such as difficulty controlling anger and / or disruptive behavior. In some embodiments, the method reduces one or both of these symptoms. In some embodiments, the subject has a comorbid condition of anxiety, and in some cases, the method reduces the anxiety symptoms. In some embodiments, the subject has OCD, and in some cases, the method reduces the OCD symptoms. In some embodiments, the subject has a comorbid condition of self-injurious dermatopathy, such as excessive skin picking, and the method reduces those symptoms. In some embodiments, the subject has one or more comorbid developmental disorders, and in some cases, the method reduces the severity of symptoms related to the developmental disorder.

[0019] In some embodiments, the method can reduce behavioral symptoms of ADHD, such as inattention, hyperactivity, and / or impulsivity. In some embodiments, the method also includes evaluating symptoms, such as inattention, hyperactivity, and / or impulsivity, during or after administration, for example, to determine whether one or more of those symptoms are reduced in the subject. In some methods, such evaluation can be based on an ADHD rating scale, or can be based on a Clinical Global Impression (CGI) scale, such as a CGI-Severity or CGI-Improvement scale. For example, in some embodiments, the method further includes obtaining a clinical global impression of the subject's severity or improvement during or after administration. In some embodiments, the method can improve the Clinical Global Improvement score and / or the ADHD rating scale score in the subject. In some cases, the symptoms can be reduced after at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks of treatment with the activator.

[0020] In some embodiments of the above ADHD treatment methods, the subject has at least one genetic alteration, such as a point mutation, an insertion, a deletion, or a copy number variation (CNV), in an mGluR network gene. In some embodiments, the subject has genetic alterations in two or more mGluR network genes. In some embodiments, the genetic alteration is detected by a process that includes a genetic test that includes obtaining a sample from a subject, optionally isolating nucleic acid from the sample, optionally amplifying the nucleic acid, and analyzing the nucleic acid for a genetic alteration in at least one mGluR network gene.

[0021] In some embodiments, the method of treatment further comprises obtaining the results of a genetic test prior to the first administration of the activator, hi some embodiments, the genetic test comprises analyzing nucleic acid for CNVs or SNVs in at least 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes (FIG. 1 herein).

[0022] In some embodiments, the genetic test comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 30, 50, 100, 150, 175, or all of the Tier 2 mGluR network genes (Figure 2). In some embodiments, the method comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 50, 100, 200 300, 400, 500, or all of the Tier 3 mGluR network genes (Figure 3). In some embodiments, the genetic test does not evaluate one or more CNVs and SNVs of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, or GRM8. In some embodiments, the subject does not have one or more CNVs and SNVs of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, or GRM8.

[0023] Further provided herein is a method for treating ADHD in a subject, comprising administering fasoracetam to the subject at a dose of 50-400 mg, for example, 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, administered once, twice or three times a day, to treat ADHD. In some such embodiments, fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg or 400 mg twice a day, for example, 100-200 mg twice a day.

[0024] In some embodiments of the above ADHD treatment methods, the subject has at least one genetic alteration, such as a point mutation, an insertion, a deletion, a single nucleotide variation (SNV) or a copy number variation (CNV), in an mGluR network gene. In some embodiments, the subject has genetic alterations in two or more mGluR network genes. In some embodiments, the genetic alteration is detected by a process comprising a genetic test, including obtaining a sample from a subject, optionally isolating nucleic acid from the sample, optionally amplifying the nucleic acid, and analyzing the nucleic acid for a genetic alteration in at least one mGluR network gene.

[0025] In some embodiments, the method of treatment further comprises obtaining the results of a genetic test prior to the first administration of the activator. In some embodiments, the genetic test comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all of the Tier 1 mGluR network genes (FIG. 1 herein). In some embodiments, the genetic test comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 30, 50, 100, 150, 175, or all of the Tier 2 mGluR network genes (FIG. 2).

[0026] In some embodiments, the method includes analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 50, 100, 200 300, 400, 500, or all of the Tier 3 mGluR network genes (Figure 3). In some embodiments, the genetic test does not evaluate CNVs and SNVs of one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, or GRM8.

[0027] In some embodiments, the ADHD subject has a genetic alteration, e.g., a CNV, in a Tier 1 or Tier 2 mGluR network gene, but no genetic alteration, e.g., a CNV, in a Tier 3 mGluR network gene, hi some embodiments, the test utilizes a solid support, microarray, or chip containing appropriate probes to detect the presence of genetic CNVs and / or SNVs.

[0028] In some embodiments, the subject is a child or adolescent subject, e.g., a subject between the ages of 5 and 17, between 8 and 17, between 5 and 12, between 5 and 8, between 8 and 12, between 12 and 18, between 13 and 18, or between 12 and 17. In other embodiments, the subject is an adult.

[0029] In some embodiments, fasoracetam is used in combination with stimulants such as methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, or lisdexamfetamine, and / or in combination with non-stimulants such as atomoxetine, clonidine, or guanfacine, and / or in combination with antidepressants such as fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, or monoamine oxidase inhibitors, and / or in combination with antianxiety drugs such as barbiturates, pregabalin, or benzodiazepines (clomid, clonidine, sirolimus ...

[0043] In some embodiments, the medicament may be administered in combination with a medicament such as azepam, azepam oxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam or midazolam, and / or in combination with an antipsychotic, such as aripiprazole or risperidone, and / or in combination with a beta-blocker, such as acebutolol, atenolol, betaxolol, bisoprolol, esmolol, nebivolol, metoprolol, cartelol, penbutolol, pindolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, propranolol, sotalol or timolol.

[0030] In some embodiments, fasoracetam is administered in combination with a non-pharmacological therapy, such as brain stimulation, for example vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetoconvulsive therapy, and / or deep brain stimulation.

[0031] In some embodiments, the ADHD subject has at least one comorbid phenotype or condition, such as oppositional defiant disorder (ODD), anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, 22q deletion or duplication syndrome, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder. In some embodiments, the subject does not have at least one comorbid phenotype, such as ODD, anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, 22q deletion or duplication syndrome, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder, or does not have any such comorbid phenotype.

[0032] In some embodiments, the subject has ODD. In some such embodiments, the method treats ODD in the subject by, for example, reducing symptoms of argumentativeness and rebelliousness, vengefulness, and / or anger and irritability. In some embodiments, the subject has ODD and ADHD.

[0033] In some embodiments, the ADHD subject has a comorbid phenotype, such as a mood disorder or a sleep disorder, such as insomnia. In some embodiments, the method treats the mood or sleep disorder, for example, by reducing a symptom thereof. In some embodiments, the subject has a comorbid symptom of anxiety, and in some cases, the method reduces the anxiety symptom. In some embodiments, the subject has OCD, and in some cases, the method reduces the OCD symptom. In some embodiments, the subject has a comorbid symptom of a self-injurious dermatopathy, such as excessive skin picking, and in some cases, the method reduces the symptom. In some embodiments, the subject has one or more comorbid developmental disorders, and in some cases, the method reduces the severity of a symptom associated with the developmental disorder.

[0034] For example, in some embodiments, the method can reduce behavioral symptoms of ADHD, such as inattention, hyperactivity, and / or impulsivity. In some embodiments, the method also includes evaluating symptoms, such as inattention, hyperactivity, and / or impulsivity, during or after administration, for example, to determine whether one or more of those symptoms in the subject have been reduced. In some methods, such evaluation can be based on an ADHD rating scale, or based on a Clinical Global Impression (CGI) scale, such as a CGI-Severity or CGI-Improvement scale. For example, in some embodiments, the method further includes obtaining a Clinical Global Impression of the subject's severity or improvement during or after administration. In some cases, the symptoms can be reduced after at least 1 week, at least 2 weeks, at least 3 weeks, or at least 4 weeks of treatment with the activator.

[0035] In some embodiments, the method can improve the subject's Clinical Global Improvement score and / or ADHD rating scale score. For example, in any of the above ADHD treatment methods, the subject can have one or more of the following symptomatic changes after at least 1, 2, 3, or 4 weeks of treatment with the activator: (a) the subject has symptoms of anger control and those anger control symptoms are reduced; (b) the subject has symptoms of disruptive behavior and those disruptive behavior symptoms are reduced; (c) the subject's CGI-I is reduced by at least 1 or at least 2; (d) the subject's CGI-I score after 1, 2, 3, or 4 weeks of treatment is 1 or 2; (e) the subject's CGI-S score after 1, 2, 3, or 4 weeks of treatment is 1; (f) the subject's ADHD rating scale score is reduced by at least 25%, e.g., at least 30%, at least 35%, or at least 40%; (g) the subject has symptoms of inattention and / or depression and / or anxiety ... (h) the subject has a symptom of hyperactivity and the hyperactivity symptom is reduced; (i) the subject has a symptom of impulsivity and the impulsivity symptom is reduced; (j) the subject has a symptom of ODD, e.g., anger and irritability, argumentative and defiant attitudes, and / or vindictiveness and the ODD symptom is reduced; (k) the subject has a symptom of conduct disorder and the conduct disorder symptom is reduced; (l) the subject has a symptom of anxiety and the anxiety symptom is reduced; (m) the subject has a symptom of Tourette's syndrome and the Tourette's syndrome symptom is reduced; (n) the subject has a symptom of autism and the autism symptom is reduced; and (o) the subject has a symptom of movement disorder and the movement disorder symptom is reduced.

[0036] In some embodiments, where an ADHD subject has at least one genetic alteration in an mGluR network gene, the genetic alteration is detected by a process comprising a genetic test that includes obtaining a sample from a subject, optionally isolating nucleic acid from said sample, optionally amplifying said nucleic acid, and analyzing said nucleic acid for a genetic alteration in at least one mGluR network gene.

[0037] In some embodiments, the method of treatment further comprises obtaining the results of a genetic test prior to the first administration of the activator, hi some embodiments, the genetic test comprises analyzing nucleic acid for CNVs or SNVs in at least 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes (FIG. 1 herein).

[0038] In some embodiments, the genetic testing comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 30, 50, 100, 150, 175, or all of the Tier 2 mGluR network genes (Figure 2). In some embodiments, the method comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 50, 100, 200 300, 400, 500, or all of the Tier 3 mGluR network genes (Figure 3).

[0039] In some embodiments, the genetic test does not assess CNVs and SNVs of one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, or GRM8. In some embodiments, the subject does not have CNVs and SNVs of one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, or GRM8. In some embodiments, the ADHD subject has a genetic alteration, e.g., a CNV, in a Tier 1 or Tier 2 mGluR network gene, but does not have a genetic alteration, e.g., a CNV, in a Tier 3 mGluR network gene.

[0040] Also provided herein is a method for treating 22q syndrome in a subject, comprising administering an effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject with 22q syndrome to treat 22q syndrome. In some embodiments, the subject has a genetic alteration of gene RANBP1, such as a point mutation, an insertion, a deletion, or a copy number variation (CNV). For example, the subject may have a deletion or duplication of 22q11.2, i.e., 22q deletion or 22q duplication syndrome. In some embodiments, the method provided comprises treating 22q deletion syndrome in a subject, wherein the treatment comprises administering an effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject with 22q deletion syndrome to treat 22q deletion syndrome.

[0041] In some embodiments, the method provided is a method for treating 22q duplication syndrome in a subject, comprising administering an effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject with 22q duplication syndrome to treat 22q deletion syndrome. In some embodiments, the subject has a genetic alteration in RANBP1 and has a genetic alteration in at least one additional mGluR network gene, such as a Tier 1, Tier 2 or Tier 3 gene as disclosed in Figures 1-3 herein. In some embodiments, the subject does not have a CNV and single nucleotide variation (SNV) in one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

[0042] In some embodiments, the 22q syndrome subject has Attention Deficit Hyperactivity Disorder (ADHD), and treating the subject can include treating ADHD, e.g., alleviating at least one ADHD symptom in the subject, including inattention, hyperactivity, and impulsivity. In some embodiments, the subject is a child or adolescent subject, e.g., a subject between the ages of 5 and 17 years old, between 8 and 17 years old, between 5 and 12 years old, between 5 and 8 years old, between 8 and 12 years old, between 12 and 18 years old, between 13 and 18 years old, or between 12 and 17 years old. In other embodiments, the subject is an adult.

[0043] In some embodiments, the non-selective mGluR activator is fasoracetam, for example, fasoracetam monohydrate (NFC-1).

[0044] In some embodiments where the activator is fasoracetam, fasoracetam is administered at a dose of 50-400 mg, e.g., 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, administered once, twice or three times daily. In some embodiments, fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg or 400 mg twice daily, e.g., 100-200 mg twice daily.

[0045] In some embodiments, the activator is administered in combination with another pharmaceutical agent, e.g., a stimulant, e.g., methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, or lisdexamfetamine, and / or in combination with a non-stimulant, e.g., atomoxetine, clonidine, or guanfacine, and / or in combination with an antidepressant, e.g., fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, or monoamine oxidase inhibitors, and / or in combination with an antianxiety agent, e.g., barbiturates, pregabalin, or benzodiazepines. in combination with an antipsychotic, such as aripiprazole, in combination with an antipsychotic, such as chlordiazepoxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam or midazolam; It is administered in combination with zole or risperidone, and / or in combination with a beta-blocker such as acebutolol, atenolol, betaxolol, bisoprolol, esmolol, nebivolol, metoprolol, cartelol, penbutolol, pindolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, propranolol, sotalol, or timolol.

[0046] In some embodiments, the activator is administered in combination with a non-pharmacological therapy, for example, brain stimulation, for example, vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetoconvulsive therapy, and / or deep brain stimulation.

[0047] In some embodiments, the 22q deletion and / or duplication syndrome subject may have at least one co-morbid phenotype or condition, such as oppositional defiant disorder (ODD), anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder. In some embodiments, the subject does not have at least one of oppositional defiant disorder (ODD), anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder, or in some embodiments, does not have any of these co-morbid conditions.

[0048] In some embodiments, the 22q deletion and / or duplication subject has ADHD, the subject does not have at least one of ODD, conduct disorder, anxiety disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder. In some embodiments, the subject does not have any of ODD, conduct disorder, anxiety disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder. In some embodiments, the 22q deletion and / or duplication subject also has a mood disorder or sleep disorder, such as insomnia. In some such embodiments, the method treats the mood or sleep disorder, for example, by reducing the symptoms thereof. In some embodiments, the subject has ODD. In some such embodiments, the method treats the ODD in the subject, for example, by reducing the symptoms of argumentativeness and defiance, vindictiveness, and / or anger and irritability. In some embodiments, the subject has a comorbid condition of anxiety, and optionally the method reduces the anxiety symptoms. In some embodiments, the subject has OCD, and optionally the method reduces the OCD symptoms. In some embodiments, the subject has a comorbid condition of self-injurious dermatopathy, such as excessive skin picking, and optionally the method reduces those symptoms. In some embodiments, the subject has one or more comorbid developmental disorders, and optionally the method reduces the severity of symptoms related to the developmental disorder.

[0049] 22q syndrome can be diagnosed in a subject by tests currently used to determine the presence of 22q deletions or duplications. In some embodiments, a subject is diagnosed by a process that includes a genetic test to detect the presence or absence of a deletion or duplication at 22q11.2 and / or the presence or absence of a genetic alteration in RANBP1 in a sample from the subject. In some embodiments, the treatment method includes obtaining the results of a genetic test for 22q (e.g., the presence or absence of a deletion or duplication at 22q11.2 and / or the presence or absence of a genetic alteration in RANBP1 in a sample from the subject) prior to the first administration of the activator. In some embodiments, the activator is administered in an amount or dosage regimen that has been proven effective to obtain a Clinical Global Impression-Improvement (CGI-I) score of 1 or 2 after 4 weeks of treatment in a majority of subjects in at least one clinical trial, and / or an improvement of at least 25%, e.g., at least 30%, at least 35%, or at least 40% in ADHD rating scale score after 4 weeks of treatment. In any of the above embodiments, 22q syndrome may be considered to be treated in some cases when the neurobehavioral, neuropsychiatric and neurodevelopmental symptoms associated with 22q deletion and / or duplication syndrome are alleviated. Such symptoms include, but are not limited to, improvements in memory, attention, cognition, anxiety, and stabilization or reversal of mood disorders, autism spectrum disorder, psychosis and hyperactivity. In any of the above embodiments, 22q deletion and / or duplication syndrome may be considered to be treated in some cases when at least one symptom of ADHD is improved in the subject. For example, in some embodiments, the method may reduce behavioral symptoms, such as inattention, hyperactivity and / or impulsivity. In some embodiments, the method may also include evaluating symptoms, such as inattention, hyperactivity and / or impulsivity, and anger control and / or disruptive behavior, during or after administration, to determine whether one or more of those symptoms are reduced in the subject. In some methods, such assessment can be based on an ADHD rating scale, or can be based on a Clinical Global Impression (CGI) scale, such as the CGI-Severity or CGI-Improvement scale.For example, in some embodiments, the method further comprises obtaining a clinical global impression of the subject's severity or improvement during or after administration. In some embodiments, the method can improve the clinical global improvement score and / or ADHD rating scale score in the subject. For example, in any of the above 22q deletion and / or duplication syndrome treatment methods, the subject can have one or more of the following changes in symptoms after at least 1, 2, 3, or 4 weeks of treatment with the activator: (a) the subject has symptoms of anger control and those anger control symptoms are reduced; (b) the subject has symptoms of disruptive behavior and those disruptive behavior symptoms are reduced; (c) the subject's CGI-I is reduced by at least 1 or at least 2; (d) the subject's CGI-I score after 1, 2, 3, or 4 weeks of treatment is 1 or 2; (e) the subject's CGI-S score after 1, 2, 3, or 4 weeks of treatment is 1; (f) the subject's ADHD rating scale score is reduced by at least 25%, e.g., at least 30%, at least 35%, or at least 40%; (g) (h) the subject has a symptom of hyperactivity and their hyperactivity symptom is reduced; (i) the subject has a symptom of impulsivity and their impulsivity symptom is reduced; (j) the subject has a symptom of ODD, e.g., anger and irritability, argumentative and defiant attitudes, and / or vindictiveness and their ODD symptom is reduced; (k) the subject has a symptom of conduct disorder and their conduct disorder symptom is reduced; (l) the subject has a symptom of anxiety and their anxiety symptom is reduced; (m) the subject has a symptom of Tourette's syndrome and their Tourette's syndrome symptom is reduced; (n) the subject has a symptom of autism and their autism symptom is reduced; and (o) the subject has a symptom of movement disorder and their movement disorder symptom is reduced.

[0050] Additional objects and advantages will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice. The objects and advantages will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.

[0051] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the scope of the present invention.

[0052] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate one or more embodiments and together with the description serve to explain the principles described herein. [Brief description of the drawings]

[0053] [Figure 1] Figure 1 shows the mGluR network genes included in the Tier 1 gene set. These genes have a protein-protein interaction degree of 2 with mGluR genes (GRM1-8) based on Cytoscape Human Interactome, a software for integrating biomolecular interaction networks with high-throughput data (described in Shannon P (2003) Genome Research 13:2498-2504). The Tier 1 gene set contains 76 genes. The exact locus for each gene in Tier 1 is listed in both Human Genome version 18 (hg18) and Human Genome version 19 (hg19). In addition, hg19 lists the exact gene locus +500 kilobases (i.e., ranging from 500 kilobases before to 500 kilobases after the gene of interest). The first single nucleotide polymorphism (StartSNP) (i.e., the SNP located 500 kilobases before the gene of interest) and EndSNP (i.e., the SNP located 500 kilobases after the gene of interest) are also listed. The mGluR gene itself is designated "GRM." The extension regions (i.e., upstream and downstream of the 500 kb) often carry regulatory elements that, if affected by CNVs, can have the same effect on gene expression and function as CNVs present in the gene sequence itself. [Diagram 2]Figure 1 shows the mGluR network genes included in the Tier 2 gene set. These genes have a protein-protein interaction degree of 2 with mGluR genes (GRM1-8) based on Cytoscape Human Interactom, but do not include genes from Tier 1. The Tier 2 gene set includes 197 genes. The exact locus for each gene in Tier 2 is listed in both Human Genome version 18 (hg18) and Human Genome version 19 (hg19). In addition, hg19 lists the exact gene locus +500 kb (i.e., ranging from 500 kb before to 500 kb after the gene of interest). The first single nucleotide polymorphism (StartSNP) (i.e., the SNP located 500 kb before the gene of interest) and EndSNP (i.e., the SNP located 500 kb after the gene of interest) are also listed in hg19. [Diagram 3] Figure 1 shows genes in the Tier 3 gene set. Genes with a counterpart gene, based on Cytoscape Human Interactom, are included when searching for a protein-protein interaction degree of 2 with mGluR genes. Genes included in Tier 1 and 2 are excluded from Tier 3. The Tier 3 gene set contains 599 genes. The exact locus for each Tier 3 gene is listed in both Human Genome version 18 (hg18) and Human Genome version 19 (hg19). In addition, hg19 lists the exact gene locus +500 kb (i.e., the range from 500 kb before to 500 kb after the gene of interest). The StartSNP (i.e., the SNP located 500 kb before the gene of interest) and EndSNP (i.e., the SNP located 500 kb after the gene of interest) are also listed in hg19. [Figure 4]FIG. 1 shows the percentage of subjects in the Phase Ib clinical trial described in Example 1 who were considered responders to NFC-1 based on having a Clinical Global Impression-Improvement (CGI-I) score of 1 or 2 (moderately improved or markedly improved) each week of the dose escalation phase from Week 1 (placebo baseline) to Week 5 of the clinical trial, based on both the total study population and genetic tier (1, 2 or 3). [Figure 5a-5b] Figure 5 shows the percentage of clinical trial subjects who showed improvement in Vanderbilt ADHD score each week compared to either pre-study baseline (Figure 5a) or placebo baseline (week 1) (Figure 5b) for both gene tier and total study population. A reduction of at least 25% in Vanderbilt ADHD score is considered responsiveness and improvement. [Figure 6a-6b] Figure 6 shows the percentage of clinical trial subjects who showed strong improvement in Vanderbilt ADHD score each week compared to either pre-study baseline (Figure 6a) or placebo baseline (week 1) (Figure 6b), for both genetic tier and total study population. A reduction of at least 40% in Vanderbilt ADHD score is considered a strong improvement. [Figure 7a-7b] FIG. 7 shows the percentage of clinical trial subjects who completed the full dose escalation to 400 mg NFC-1 twice daily at week 5 and who demonstrated improvement in Vanderbilt ADHD score each week compared to either pre-study baseline (FIG. 7a) or placebo baseline (week 1) (FIG. 7b), for both genetic tier and total study population. A reduction of at least 25% in Vanderbilt ADHD score is considered an improvement. [Figure 8a-8b] FIG. 8 shows the percentage of clinical trial subjects who completed the full dose escalation to 400 mg NFC-1 twice daily at week 5 and who demonstrated a strong improvement in Vanderbilt ADHD score each week compared to either pre-study baseline ( FIG. 8a ) or placebo baseline (week 1) ( FIG. 8b ), for both genetic tier and total study population. A reduction of at least 40% in Vanderbilt ADHD score is considered a strong improvement. [Figure 9a]Figure 1 shows results from actigraphy testing in clinical trial subjects by genetic tier group. The decline observed in moderate-to-vigorous physical activity (MVPA) from week 1 (placebo) to week 5 for genetic Tier-1 was most pronounced in the 400 mg bid dose group. [Figure 9b] Figure 1 shows results from actigraphy testing in clinical trial subjects by genetic tier group. The decline observed in moderate-to-vigorous physical activity (MVPA) from week 1 (placebo) to week 5 for genetic Tier-2 was most pronounced in the 400 mg bid dose group. [Figure 9c] Figure 1 shows results from actigraphy testing of subjects in a clinical trial by genetic tier group. The decline observed in moderate-to-vigorous physical activity (MVPA) from week 1 (placebo) to week 5 for genetic Tier-3 was most pronounced in the 400 mg bid dose group. [Figure 10] FIG. 13 shows that clinical trial subjects in the Tier-1 genogroup had a significant improvement in the QUOTIENT® ADHD Test measure of inattention from week 1 (placebo) to week 5 (400 mg twice daily) as shown by a reduction in inattention in the Tier-1 group from a normalized inattention value of just over 100 to approximately 90 between week 4 (200 mg twice daily) and week 5 (400 mg twice daily) of dose escalation (P<0.05). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0054] I. Definition In addition to the definitions contained in this subsection, further definitions of terms are scattered throughout this document.

[0055] In the present invention, unless the context clearly dictates otherwise, "a" or "an" means "at least one" or "one or more," etc. The term "or" means "and / or," unless otherwise indicated. However, in the case of a multiple dependent claim, the use of the term "or" refers back to more than one preceding claim solely in the alternative.

[0056] "mGluR" or metabotropic glutamate receptor refers to one of eight metabotropic glutamate receptors expressed in neural tissue, named mGluR1, mGluR2, mGluR3, mGluR4, mGluR5, mGluR6, mGluR7, and mGluR8. Their genes are abbreviated as GRM1 through GMRM8. mGluR proteins are G protein-coupled receptors. They are typically classified into three subgroups: Group I receptors, which include mGluR1 and mGluR5, are classified as slow excitatory receptors; Group II includes mGluR2 and mGluR3; Group III includes mGluR4, mGluR6, mGluR7, and mGluR8; Groups II and III are classified as slow inhibitory receptors. mGluRs are distinct from ionotropic GluRs or iGluRs, which are ionotropic glutamate receptors and are classified as fast excitatory receptors.

[0057] "mGluR network genes", as used herein, include not only the mGluRm genes GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, and GRM8, but also each of the other genes listed in Figures 1-3 herein, as well as regions of DNA that regulate the genes listed in Figures 1-3. In addition, "mGluR network proteins" are proteins encoded by mGluR network genes.

[0058] The mGluR network genes are classified into three subsets: Tier 1, Tier 2, and Tier 3. (See Figures 1-3.) The Tier 1 mGluR network genes shown in Figure 1 contain 76 genes, including several GRM genes themselves as well as many other genes. The Tier 2 mGluR network genes shown in Figure 2 contain 197 genes and do not include the Tier 1 genes.

[0059] Both Tier 1 and 2 are included in the "primary mGluR network". The "primary network" of mGluR genes is a total of 276 genes, including genes 4-Sep, LOC642393 and LOC653098. The evaluation of 4-Sep, LOC642393 and LOC653098 genes is difficult with current technology. Therefore, they are not included in Tier 1 and Tier 2, but are included in the primary network of genes of the present invention. Tier 1 and 2 genes differ in that alterations in Tier 1 genes have been documented in previous genotyping studies of subjects suffering from psychiatric disorders.

[0060] The Tier 3 mGluR network genes shown in Figure 3 include 599 genes that are in the distal part of the mGluR network based on the merged human interactome provided by Cytoscape software (Shannon P et al. (2003) Genome Research 13:2498- 2504), and do not include Tier 1 or Tier 2 genes. Thus, Tier 3 genes are part of the "distal mGluR network." In addition to the Tier 3 genes, genes LOC285147, LOC147004, and LOC93444 are also included in the "distal mGluR network," but due to technical difficulties, they were not evaluated in this study and are not included in Tier 3.

[0061] As used herein, "genetic alteration" refers to any alteration in the DNA of a gene or in the DNA regulating a gene that can result in, for example, a functionally altered gene product compared to the gene product produced from unaltered DNA. A functional alteration can be, for example, a different expression level (up-regulation or down-regulation), or a loss or alteration of one or more biological activities. Genetic alterations include, but are not limited to, copy number variations (CNVs), single nucleotide variations (SNVs) (also referred to herein as single nucleotide polymorphisms (SNPs)), frameshift mutations, or any other base pair substitutions, insertions, and deletions.

[0062] "Copy number variation" or "CNV" is a duplication or deletion of a DNA segment when compared to a reference genome, the DNA segment encompassing a gene, genes, a segment of a gene, or a DNA region regulating a gene. In some embodiments, CNV is determined based on a change from a normal diploid state. In some embodiments, CNV represents a copy number change involving a DNA fragment that is 1 kilobase (kb) or larger. CNV as described herein does not include variants resulting from insertion / deletion of transposable elements (e.g., 6 kb KpnI repeats). Thus, the term CNV encompasses terms such as large copy number variation (LCV; Iafrate et al., 2004), copy number polymorphism (CNP; Sebat et al., 2004), and intermediate size variant (ISV; Tuzun et al., 2005), but does not encompass retrotransposon insertions.

[0063] "CNV deletion" or "deletion CNV" or similar terms refer to a CNV in which a gene or gene segment is deleted. "CNV duplication" or "duplication CNV" or similar terms refer to a CNV in which a gene or gene segment is present in at least two copies, and possibly more than two copies, compared to the single copy found in the normal reference genome.

[0064] "Sample" refers to a sample from a subject that can be tested, for example, for the presence of a CNV in one or more mGluR network gene proteins, as described herein. A sample can include cells or can include bodily fluids, such as blood, serum, plasma, cerebrospinal fluid, urine, saliva, tears, pleural fluid, etc.

[0065] As used herein, "22q syndrome" and "22q11.2 syndrome" are used interchangeably.

[0066] The terms "pediatric subject" or "pediatric patient" are used interchangeably to refer to a human under the age of 18. An "adult patient" or "adult subject" refers to a human over the age of 18. An "adolescent patient" or "adolescent subject" is typically between about 12 and 18 years of age, e.g., between 12 and 17 years of age, or between 13 and 18 years of age.

[0067] II. Attention Deficit Hyperactivity Disorder (ADHD) The term "attention deficit hyperactivity disorder" or ADHD refers to a heterogeneous disorder that may be characterized at least in part by inattention, hyperactivity, and impulsivity. Symptoms of ADHD include difficulty concentrating and paying attention, difficulty controlling behavior, and hyperactivity. According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), a physician may diagnose ADHD when a subject shows a persistent pattern of inattention or hyperactivity-impulsivity that interferes with the subject's functioning or development. ADHD can occur in at least 5% of the population and can be diagnosed in both adult and pediatric subjects.

[0068] There are three classes of ADHD: predominantly hyperactive-impulsive, predominantly inattentive, and mixed hyperactive-impulsive-inattentive. Patients with predominantly hyperactive-impulsive have more hyperactivity-impulsivity than inattention. Patients with predominantly inattentive lack attention but have fewer hyperactivity-impulsivity symptoms, these patients may be able to sit quietly in class but not pay attention to the tasks they need to do. Patients with mixed hyperactive-impulsive-inattentive have significant symptoms of both inattention and hyperactivity-impulsivity. Mixed ADHD is the most common type in children. Each of the methods described herein encompasses the treatment of all classes of ADHD.

[0069] ADHD is a heterogeneous condition and may result from a combination of factors, such as genes, environmental factors, and / or brain damage. In addition, ADHD patients are significantly more likely than normal individuals to have genetic alterations, e.g., CNVs, in at least one mGluR network gene. (See WO 2012 / 027491 and U.S. Patent Application Publication No. 2013 / 0203814; Elia et al., Nature Genetics, 44(1):78-84 (2012)).

[0070] The currently approved treatments for ADHD include neurostimulants, such as methylphenidate and amphetamine, and non-neurostimulants, such as atomoxetine.Antidepressants, such as serotonin selective uptake inhibitors, such as fluoxetine, sertraline and citalopram, as well as clonidine and guanfacine, can also be administered in some cases.However, these drugs can have many potential side effects, and some also have a short active half-life.

[0071] Some subjects with ADHD may have one or more comorbid disorders, such as oppositional defiant disorder (ODD), anxiety disorder, mood disorder, phobia, obsessive-compulsive disorder (OCD), depression, conduct disorder, Tourette's syndrome, autism, or movement disorder.In other cases, ADHD subjects do not have any of ODD, anxiety disorder, mood disorder, phobia, obsessive-compulsive disorder (OCD), depression, conduct disorder, Tourette's syndrome, autism, and movement disorder.Some subjects with ADHD may also show mood disorder or sleep disorder, such as insomnia.

[0072] Approximately 40% of pediatric ADHD patients, for example, also have ODD, and some ADHD medications are believed to improve ODD symptoms as part of the treatment of ADHD. According to DSM-5, a subject may be diagnosed with ODD if they exhibit at least four symptoms of anger and irritable mood, argumentative defiant behavior, or vindictiveness that occur with at least one individual other than a sibling, cause significant problems at work, school, or home, and persist for at least six months. Symptoms of anger and irritable mood include: often loses his / her temper; often has a short temper or is easily annoyed by others; often is angry and resentful. Symptoms of argumentative defiant behavior include: often complains to adults or authority figures, often actively ignores or refuses to comply with adult requests or rules, often intentionally annoys people, and often blames others for his / her own mistakes or misdeeds. Symptoms of vindictiveness include: often is spiteful or vindictive, and has exhibited spiteful or vindictive behavior at least twice within the past six months. These symptoms must occur independently and not as part of the process of another mental health problem, such as substance abuse, depression, or bipolar disorder. A person aged 5 years or older may be diagnosed with ODD if the symptoms occur at least once a week for at least six months. Thus, a subject with "ODD" is defined herein as a person who has been diagnosed with ODD based on the DSM-5 criteria above.

[0073] Subjects with ADHD, whether or not diagnosed with a comorbid disorder, may also exhibit a variety of additional behavioral phenotypes, such as anger control difficulties and disruptive behaviors.

[0074] Other comorbid disorders that ADHD subjects may suffer from include obsessive-compulsive disorder (OCD), developmental disorders, or self-injurious dermatopathy. "Developmental disorders" in this specification include, for example, those classified under International Classification of Diseases, 9th Edition (World Health Organization) codes 299.80, 299.90, 315.2, 315.39, 315.4, 315.5, 315.8, and 315.9, which may affect behaviors such as learning, coordination, and speech. "Self-injurious dermatopathy," also known as excoriation disorder or skin picking, is a disorder that involves excessive picking of one's own skin, causing damage, and includes picking of normal skin as well as real or imagined skin defects, such as moles, freckles, or scars.

[0075] III.22q syndrome The terms "22q syndrome" or "22q11 syndrome" or "22q11.2 syndrome" are used interchangeably herein to refer to subjects whose genome contains a CNV in the q11.2 region of chromosome 22, which contains the RANBP1 mGluR network gene locus. RANBP1 encodes a protein that interacts with mGluR3. Subjects with "22q Deletion Syndrome" or "22qDS" or "22q11.2DS" have a deletion in that chromosomal region, while subjects with "22q Duplication Syndrome" or "22qDupS" or "22q11.2DupS" have a duplication in that region.

[0076] Deletion of a small piece of chromosome 22, q11.2, containing the RANBP1 mGluR network gene locus, is called "22q deletion syndrome" or "22q11.2DS." 22q deletions are frequent, involving deletions of approximately 30 to 40 genes, including RANBP1, and can be characterized by heart defects, cleft palate, and distinctive facial features, as well as low intelligence levels. Approximately 37% of children with 22q11.2DS are also diagnosed with ADHD. Children with 22q11.2DS also have high rates of autism spectrum disorder (ASD) and anxiety disorders, and a significant proportion may develop psychoses, such as schizophrenia, later in life. 22q11.2DS occurs in approximately 1 in 2,000-4,000 people, but this may be a low estimate, as mild cases cannot always be diagnosed. Before the genetic basis of 22q11.2DS was understood, the distinct group of manifestations of 22q11.2DS were previously called DiGeorge syndrome, palatocardiofacial syndrome, and conotruncal dysfacies syndrome.

[0077] Duplications at q11.2 on chromosome 22, including the RANBP1 locus, are referred to as "22q duplication syndrome," "22q11.2 duplication syndrome," or "22q11.2DupS," and can be characterized by intellectual / learning disabilities, neuromotor developmental delay, growth retardation, and hypotonia. The frequently duplicated piece of chromosome 22 in 22q11.2DupS is often the same as the frequently deleted piece in 22q11.2DS, which contains 30-40 genes. The incidence of 22q11.2DupS in patients examined by genomic microarray analysis for developmental delay or intellectual disability is approximately 1 in 300-700.

[0078] Diagnostic tests available for 22q11.2DS include targeted variant analysis (which looks for variants in a panel of targets), fluorescent in situ hybridization (FISH), and sequence coding of the entire coding region. Diagnostic tests available for 22q11.2DupS include chromosomal microarray and FISH methods.

[0079] IV. mGluR network genes In some embodiments herein, ADHD patients may be evaluated for genetic alterations in one or more of the Tier 1, 2 and / or 3 mGluR network genes, e.g., a single gene or a panel of such genes, prior to treatment. In some embodiments, the genetic alteration is a copy number variation (CNV) resulting from duplication or other multiple duplication of one or both copies of a gene or deletion of one or both copies of a gene. CNV deletions or duplications can alter the expression of the resulting gene product contained within the CNV due to changes in the copy number of this gene, and thus may contribute to the disease phenotype. However, CNV deletions or duplications also do not affect the relative expression of the gene product in any tissue (see Henrichsen CN et al. (2009) Human Molecular Genetics, 2009, Vol. 18(1):R1-R8). CNV deletions or duplications can also affect the expression of genes located near the CNV, and therefore may affect the expression of genes outside the actual CNV. CNVs can also affect gene expression by perturbing transcript structure: for example, overlapping CNVs may result in increased copy number but may actually result in decreased gene product because they interfere with normal transcription.

[0080] In some embodiments, ADHD patients are treated who have at least one genetic alteration, e.g., at least one CNV, of an mGluR network gene, e.g., a Tier 1, Tier 2, and / or Tier 3 gene as shown in Figures 1-3. In some embodiments, the patient has a genetic alteration, e.g., a CNV, e.g., a deletion or duplication, involving the gene RANBP1, a gene that may be deleted or duplicated in 22q syndrome.

[0081] In some embodiments, gene sets or panels of mGluR network genes are used to analyze samples from patients suspected of having ADHD or 22q deletion and / or duplication syndrome. In some embodiments, the presence of genetic alterations, e.g., CNV duplications or deletions, within these gene sets or panels are determined. In some embodiments, genetic alterations, e.g., CNVs, of the Tier 1 genes shown in FIG. 1 are determined. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70 or all of the Tier 1 genes in the panel are evaluated for the presence of genetic alterations, such as CNVs. In some of these embodiments, the panel includes specific genes, such as RANBP1 or GRM1-8. Any individual specific Tier 1 gene within any such gene panel may be excluded from the panel. For example, in some embodiments, one or more of the GRM1-8 genes are not included in the panel.

[0082] In some embodiments, optionally in addition to assessing the Tier 1 assessment above, or in addition to assessing a subset of Tier 1 genes as described above, Tier 2 genes, such as those shown in Figure 2, are analyzed for the presence of genetic alterations such as CNVs. In some embodiments, at least 50 Tier 2 genes are assessed, while in some embodiments, at least 10, 20, 30, 50, 100, 150, or all Tier 2 genes are assessed. In some embodiments, individual specific Tier 2 genes may be excluded from the gene set for assessment.

[0083] In some embodiments, optionally in addition to assessing the Tier 1 and / or Tier 2 assessments above, or in addition to assessing a subset of Tier 1 and / or Tier 2 genes as described above, the 599 Tier 3 genes shown in Figure 3 are assessed for the presence of genetic alterations such as CNVs. Tier 3 genes are considered broad potential interactors with the mGluR network, and genes included in Tier 3 are not included in Tier 1 and Tier 2. In some embodiments, at least 10, 20, 50, 100, 200, 300, 400, 500, or all of the Tier 3 genes are included in the panel for assessing genetic alterations.

[0084] V. Assessment of genetic alterations in mGluR network genes Any biological sample can be used to determine the presence or absence of mGluR network genetic alterations, including but not limited to blood, urine, serum, gastric washings, central nervous system fluids, any cell type (e.g., brain cells, white blood cells, mononuclear cells) or body tissue. Any biological source from which DNA can be extracted can be used to determine the presence or absence of mGluR network genetic alterations. The sample can be freshly collected or previously collected for any use / purpose and stored until the time to test for genetic alterations. Previously purified DNA for different purposes can also be used.

[0085] A variety of methods are known for determining genetic alterations, including the following.

[0086] A. Single Nucleotide Variation (SNV) / Single Nucleotide Polymorphism (SNP) Genotyping Determining whether a patient has a genetic alteration, e.g., a CNV, in an mGluR network gene can be done by SNV / SNP genotyping using SNV / SNP genotyping arrays, such as those commercially available from Illumina or Affymetrix. "Single nucleotide variation (SNV)", also interchangeably referred to herein as "single nucleotide polymorphism (SNP)", refers to a change in DNA in which a single base differs from the normal base at that position. Millions of SNVs in the human genome have been cataloged. Some SNVs are normal variations in the genome, while others are associated with disease. Certain SNVs may be associated with disease states or susceptibility, but high-density SNV genotyping can also be undertaken, in which the sequencing information of SNVs is used to determine the unique genetic makeup of an individual.

[0087] In SNV genotyping, SNVs can be determined by hybridizing complementary DNA probes to SNV sites. A wide range of platforms can be used with SNV genotyping tools to accommodate different sample throughputs, multiplexing capabilities, and chemistries. In high-density SNV arrays, hundreds of thousands of probes are arrayed on a small chip so that many SNVs can be interrogated simultaneously as target DNA is processed on the chip. By determining the amount of hybridization of target DNA in a sample to the probes (or redundant probes) on the array, the specific SNV alleles can be determined. The use of arrays for SNV genotyping allows for large-scale interrogation of SNVs.

[0088] When analyzing CNV, after analyzing SNV, computer program can be used to manipulate SNV data to arrive at CNV data. In this case, PennCNV or similar program can be used to detect signal patterns throughout the genome and identify continuous genetic markers for copy number changes. (See Wang K et al. (June 2008) Cold Spring Harb Protoc). PennCNV allows kilobase resolution detection of CNV (See Wang K et al. (Nov 2007) Genome Res.17(11):1665-74).

[0089] In CNV analysis, SNV genotyping data is compared to the behavior of normal diploid DNA. The software uses SNV genotyping data to determine the distribution of signal intensity data and SNV allele ratios, and then uses these data to determine when there is a deviation from the normal diploid state of DNA indicative of a CNV. This is done in part by using the log R ratio (LRR), which is a normalized measure of the total signal intensity for the two alleles of an SNV (Wang 2008). If the software detects a region of adjacent SNVs with an intensity (LRR) that trends below 0, this indicates a CNV deletion. If the software detects a region of adjacent SNVs with an intensity (LRR) that trends above 0, this indicates a CNV duplication. If no change in LRR is observed compared to the behavior of diploid DNA, the sequence is in a normal diploid state with no CNV present. The software also uses the B allele frequency (BAF), which is a normalized measure of the allele intensity ratio of the two alleles that changes when an allele is lost or gained, as well as a CNV deletion or duplication. For example, CNV deletion is indicated by both a decrease in LRR value and the absence of heterozygotes in BAF value.In contrast, CNV duplication is indicated by both an increase in LRR value and the division of heterozygote genotype BAF cluster into two different clusters.The software automates the calculation of LRR and BAF to detect CNV deletion and duplication for whole genome SNV data.The simultaneous analysis of intensity data and genotype data precisely defines normal diploid state and determines CNV.

[0090] Array platforms such as those from Illumina, Affymetrix, and Agilent can be used for SNV genotyping. Custom arrays can also be designed and used based on the data described herein.

[0091] B. Comparative Genomic Hybridization Comparative genomic hybridization (CGH) is another method that can be used to evaluate genetic alterations such as CNVs. CGH is a molecular cytogenetic method that uses competitive fluorescence in situ hybridization (FISH) to analyze genetic alterations such as CNVs in comparison to a reference sample. DNA is isolated from the patient and the reference source and labeled independently with fluorescent molecules (i.e., fluorophores) after DNA denaturation. Hybridization of the fluorophores to the resulting samples is compared along the length of each chromosome to identify chromosomal differences between the two sources. Color mismatches indicate gain or loss of material in specific regions of the test sample, while color matches indicate no difference in genetic alterations such as copy number between the test sample and the reference sample in a particular region. In certain embodiments, the fluorophores are not naturally occurring.

[0092] C. Whole Genome Sequencing, Whole Exome Sequencing, and Targeted Sequencing Whole genome sequencing, whole exome sequencing, or targeted sequencing can also be used to analyze genetic changes such as CNVs. Whole genome sequencing (also known as full-length genome sequencing, complete genome sequencing, or whole genome sequencing) involves sequencing the full-length genome of a species, including protein-coding and non-coding genes. In contrast, whole exome sequencing is the sequencing of only the protein-coding genes in the genome (approximately 1% of the genome). Targeted sequencing involves sequencing only selected parts of the genome.

[0093] A wide range of techniques for performing whole genome, whole exome or targeted sequencing using purified DNA from a subject will be known to those skilled in the art.Similar techniques could be used for different types of sequencing.Technologies used for whole genome sequencing include nanopore technology, fluorophore technology, DNA nanoball technology, and pyrosequencing (i.e., sequencing by synthesis).In particular, next-generation sequencing (NGS) involves the parallel sequencing of millions of small fragments of DNA, followed by the use of bioinformatics analysis to piece together the sequencing data from said fragments.

[0094] Whole exome sequencing does not require the sequencing of a large amount of DNA as whole genome sequencing, so a wide range of techniques can be used.Methods for whole exome sequencing include polymerase chain reaction, NGS, molecular inversion probe, hybrid capture using macroarray, capture in solution, and classical Sanger sequencing.Targeted sequencing allows obtaining sequence data for specific genes instead of the whole genome, and can use any technique used for other types of sequencing, including specialized microarrays that contain materials for sequencing the gene of interest.

[0095] D. Other Methods for Determining Genetic Alterations Proprietary methods, such as those from BioNano or OpGen, that use genome mapping technology can also be used to assess genetic alterations such as CNVs.

[0096] Standard molecular biology methods, such as quantitative polymerase chain reaction (PCR), droplet PCR, and TaqMan probes (i.e., hydrolysis probes designed to increase the specificity of quantitative PCR), can be used to assess genetic alterations such as CNVs. Fluorescence in situ hybridization (FISH) probes may also be used to assess genetic alterations such as CNVs. Analysis of genetic alterations such as CNVs present in a patient is not limited by the exact method of determining genetic alterations such as CNVs.

[0097] VI. Treatment of ADHD and 22q syndrome with nonselective mGluR activators In some embodiments, a subject with ADHD is treated with a non-selective mGluR activator. In other embodiments, a subject with 22q deletion and / or duplication syndrome is treated with a non-selective mGluR activator. In yet other embodiments, a subject with ADHD and 22q deletion and / or duplication syndrome is treated with a non-selective mGluR activator. The terms "subject" and "patient" are used interchangeably to refer to a human. The terms "pediatric subject" or "pediatric patient" are used interchangeably to refer to a human under 18 years of age. In some embodiments, a subject can be between 6 and 17 years of age, e.g., between 12 and 17 years of age, or between 6 and 12 years of age. The terms "adult subject" or "adult patient" refer to a human who is at least 18 years of age. An "adolescent" subject can be, for example, between 12 and 18 years of age, e.g., between 12-17, 13-17, or 13-18 years of age.

[0098] The term "treatment" as used herein encompasses the administration or application of a treatment for a disease in a subject, including suppressing the disease, preventing its onset, alleviating one or more symptoms of the disease, or preventing the recurrence of one or more symptoms of the disease. For example, treating a 22q deletion and / or duplication syndrome subject can include alleviating the neurobehavioral, neuropsychiatric, and neurodevelopmental symptoms associated with the 22q deletion and / or duplication syndrome. Such symptoms include, but are not limited to, improving memory, attention, cognition, anxiety, and stabilizing or reversing mood disorders, autism spectrum disorders, psychosis, and hyperactivity. Treating an ADHD or 22q deletion and / or duplication subject includes alleviating symptoms of inattention, hyperactivity, and / or impulsivity associated with ADHD, and improving associated phenotypes, such as mood and sleep disorders, anger control, and disruptive behavior.

[0099] mGluR proteins are typically classified into three subgroups: Group I receptors, which include mGluR1 and mGluR5, are classified as slow excitatory receptors; Group II includes mGluR2 and mGluR3; and Group III includes mGluR4, mGluR6, mGluR7, and mGluR8. Groups II and III are classified as slow inhibitory receptors. mGluRs are distinct from ionotropic GluRs or iGluRs, which are ionotropic glutamate receptors, which are classified as fast excitatory receptors.

[0100] "Non-selective activators of mGluRs" refers to molecules that activate mGluRs from more than one of the Group I, II, and III categories. Thus, non-selective activators of mGluRs may provide a general stimulus to the mGluR network. This is in contrast to specific mGluR activators that may only significantly activate a single mGluR, such as mGluR5. Non-selective mGluR activators include, for example, non-selective mGluR agonists.

[0101] In some embodiments, the non-selective mGluR activator is "fasoracetam". Fasoracetam is a nootropic (i.e., cognitive enhancing) drug that can stimulate both group I mGluRs and group II / III mGluRs in in vitro studies. (See Hirouchi M et al. (2000) European Journal of Pharmacology 387:9-17). Fasoracetam can stimulate adenylate cyclase activity by activating group I mGluRs, while it can also inhibit adenylate cyclase activity by stimulating group II and III mGluRs. (Oka M et al. (1997) Brain Research 754:121-130). Fasoracetam has been shown in previous human studies to be highly bioavailable (79%-97%) and have a half-life of 5-6.5 hours (see Malykh AG et al. (2010) Drugs 70(3):287-312). Fasoracetam is a member of the racetam family of chemicals that share a five-carbon oxopyrrolidone ring.

[0102] The structure of Fasoracetam is: The file is TIFF2024164036000001.tif21170.

[0103] The term "fasoracetam" as used herein includes pharma- ceutically acceptable hydrates and any solid, amorphous or crystalline form of the fasoracetam molecule. For example, the term fasoracetam herein includes forms such as NFC-1, which is fasoracetam monohydrate. In addition to NFC-1, fasoracetam is also known as C-NS-105, NS105, NS-105 and LAM-105.

[0104] NFC-1 has been previously studied in Phase I-III clinical trials for dementia-related cognitive impairment, but did not show sufficient efficacy for dementia in Phase III trials. These trials demonstrated that NFC-1 is generally safe and well tolerated for these indications. Phase III data showed that NFC-1 shows beneficial effects on psychiatric symptoms in stroke patients and adult dementia patients with cerebrovascular disease. Fasoracetam is a member of the racetam family of compounds. Piracetam, another racetam compound, has been tested in pediatric ADHD subjects and found to actually increase ADHD symptoms in those subjects compared to placebo controls. (See Akhundian, J., Iranian J. Pediatrics 2001, 11(2):32-36).

[0105] In each method of treatment embodiment, a metabotropic glutamate receptor positive allosteric modulator, a metabotropic glutamate receptor negative allosteric modulator, or a tachykinin-3 / neurokinin-3 receptor (TACR-3 / NK3R) antagonist can be administered to a subject with an alteration in an mGluR network gene, either alone or in combination with, for example, a non-selective activator of mGluR. In some embodiments, the therapeutic agent comprises ADX63365, ADX50938, ADX71149, AMN082, 1-(hetero)aryl-3-amino-pyrrolidine derivatives, LY341495, ADX48621, GSK1144814, or SB223412.

[0106] VII. Methods of Administration and Dosage In some embodiments, fasoracetam can be administered as fasoracetam monohydrate (NFC-1). In some embodiments, fasoracetam can be administered via the mouth (i.e., orally). In some embodiments, fasoracetam can be administered as capsules, tablets, caplets, oral liquids, and oral suspensions. In some embodiments, fasoracetam capsules or tablets etc. can contain 50mg, 100mg, 150mg, 200mg, 250mg, 300mg, 350mg, 400mg, 600mg, or 800mg of fasoracetam, or any range of fasoracetam bounded by two of the preceding values.

[0107] In some embodiments, fasoracetam can be administered at any of the above dosages of 50mg, 100mg, 150mg, 200mg, 250mg, 300mg, 350mg or 400mg once, twice or three times a day. In some embodiments, the total daily dose of fasoracetam can be 50mg, 100mg, 150mg, 200mg, 250mg, 300mg, 350mg or 400mg administered once a day, or 50mg, 100mg, 150mg, 200mg, 250mg, 300mg, 350mg or 400mg administered twice a day. In some embodiments, a series of dose escalations can be used to adjust fasoracetam dosing. In some embodiments, pharmacokinetic data on drug levels or clinical response are used to determine changes in dosing. In some embodiments, dose escalation of fasoracetam is not used. In some embodiments, subjects are treated with a dose of fasoracetam expected to be clinically effective without a dose escalation protocol.

[0108] VIII. Therapeutic Combinations In some embodiments, the non-selective activator of mGluR network proteins, such as fasoracetam, is used in combination with other drugs for the treatment of ADHD and 22q deletion and / or duplication syndrome. In some embodiments, it is used in combination with current ADHD drugs, such as neurostimulants and / or non-stimulants. "Stimulant / neurostimulant drugs" used to treat ADHD are drugs that increase the levels of dopamine or other neurotransmitters in the brain. They are available in a variety of release forms, from short-release to sustained release. Stimulants tend to improve attention span and focus, and tend to regulate impulsive behavior. Stimulants currently in use include methylphenidate (e.g., Concerta®, Ritalin®, Daytrana® patch, Methylin®, Metadate®), dexmethylphenidate (e.g., Focalin®), and amphetamines such as Adderall XR® (amphetamine mixed salts), Dexedrine® (dextroamphetamine), and Vyvanse® (lisdexamfetamine mesylate).

[0109] "Nonsimulant / nonstimulant drugs for ADHD" (also referred to herein as "non-simulant / non-stimulant drugs") are drugs that may act on neurotransmitters but do not increase dopamine levels in the brain. Nonstimulant drugs encompass a variety of drug classes. Nonstimulant drugs currently in use include atomoxetine (Strattera®), which can prolong the action of norepinephrine in the brain, and the blood pressure drugs clonidine (Kapvay®) and guanfacine (Intuniv®), which can also improve mental function in ADHD patients.

[0110] In some embodiments, the activator may be administered in combination with an anti-anxiety drug (e.g., a barbiturate, pregabalin, or a benzodiazepine, including: chlordiazepoxide, clorazepate, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam, or midazolam). The activator may also be administered in combination with an antidepressant, such as a serotonin selective uptake inhibitor, such as fluoxetine, sertraline, and citalopram. Antidepressants include, for example, fluoxetine; escitalopram; bupropion; mirtazapine; amitriptyline; imipramine; venlafaxine; sertraline; paroxetine; or other compounds within the following classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, monoamine oxidase inhibitors; or other medications approved for use in depression. In some embodiments, the other agent may be a beta blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, esmolol, nebivolol, metoprolol, cartelol, penbutolol, pindolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, propranolol, sotalol, timolol, or other selective or nonselective blockers of beta adrenergic receptors). In some embodiments, the other agent may be an antipsychotic, e.g., aripiprazole or risperidone.

[0111] In some embodiments, fasoracetam can be used in combination with non-pharmacological treatments, such as psychotherapy or brain stimulation therapy. For example, in some embodiments, the patient is further treated with brain stimulation, which can be vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetoconvulsive therapy, deep brain stimulation, or any other therapy involving modulation of brain function by electricity, magnets, or implants.

[0112] IX. Efficacy Criteria for Determining Response to Treatment A number of different efficacy indicators and assessment scales have been found to be valid in clinical trials to determine, for example, the effectiveness of ADHD treatment. These may include attention measures, performance measures, and overall assessment measures of patient severity or improvement. Assessment scales currently used in ADHD clinical trials in pediatric patients include the ADHD Rating Scale-IV, the Vanderbilt Questionnaire, actigraphy, the Quotient ADHD test scale, and the PERMP-Math test scale. Clinical Global Impression Severity / Improvement (CGI-S and CGI-I) scores are also frequently used as secondary efficacy measures, as they correspond well to the general health status judgments that clinicians make in the usual clinical practice of treating ADHD patients.

[0113] The ADHD Rating Scale-IV is based on 18 inattention and hyperactivity / impulsivity diagnostic criteria for ADHD as found in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, 1994 (DSM-4) or 5th edition, 2016 (DSM-V) published by the American Psychiatric Association. [Are DSM-IV and DSM-V questions essentially the same?] Each of the 18 items is scored on a 4-point scale of 0, 1, 2, or 3, with 0 indicating no symptoms and 3 indicating severe symptoms. Thus, the scale allows for a score ranging from 0 to 54, with higher scores indicating greater severity of illness. There are several versions of the ADHD Rating Scale-IV, depending on who records the information, parent / teacher or clinician, and whether the patient is a pediatric or adult patient. However, all versions are designed to assess the same set of 18 items.

[0114] The Vanderbilt Rating Scale is a rating scale that can be completed by a parent or teacher (see separate forms, the Vanderbilt Rating Scale for Parents and the Vanderbilt Rating Scale for Teachers). The Vanderbilt Inventory assesses a child's behavior using items such as attention, completing tasks, hyperactivity, impatience, and measures of conduct or oppositional defiant disorder - as well as overall academic achievement and interacting with others. The first 18 items of the Vanderbilt Inventory correspond to those of the ADHD Rating Scale IV above, but the Vanderbilt Inventory also includes items 19-47 that relate to other psychiatric disorders, including ODD (items 19-26), conduct disorder (items 27-40), anxiety (items 41, 42, and 47), and depression (items 43-46). Each of the behavioral rating items on the Vanderbilt Inventory is rated 0, 1, 2, or 3, with 0=never, 1=sometimes, 2=often, and 3=very often. Thus, the ADHD Rating Scale-IV, ADHD Rating Scale-V, and Vanderbilt Rating Scale items 1-18 are equivalent scales, but additional items in the Vanderbilt Inventory assess comorbid phenotypes and disorders.

[0115] The first 18 items of the Vanderbilt Parent Rating Scale are in the form of a questionnaire and include the following: (3) Does not seem to listen when spoken to directly; (4) Does not follow through on instructions or complete activities when given (not because of refusal or inability to understand); (9) Forgetfulness in daily activities; (10) Fidgets or squirms in sitting; (16) Answers questions before they have been completed; (17) Cannot wait his / her turn. Each item is rated on a scale of 0, 1, 2, or 3, with 0=never, 1=sometimes, 2=often, and 3=very often. A total score ranging from 0 to 54 is calculated based on the responses to the 18 questions.

[0116] As used herein, "ADHD rating scale score", "ADHD score" or "Vanderbilt ADHD score" are used interchangeably to refer to the calculated score of the first 18 items of the ADHD rating scale IV or V, or related versions of the Vanderbilt rating scale, such as the version for parent, teacher or clinician completion and the version for pediatric subjects or adult subjects. Clinical trials can evaluate the impact of drugs or placebo based on the ADHD score or Vanderbilt ADHD score (i.e., a score of 0 to 54 based on the first 18 items of the ADHD or Vanderbilt rating scale). In some cases, the results of clinical trial populations can be analyzed by comparing the mean score or percentage change in score over the drug administration period. Patients can be considered "improved" if, for example, their Vanderbilt AHDH score is reduced by at least 25% compared to placebo or pre-study baseline, and can be considered "strongly improved" if, for example, their score is reduced by at least 40% compared to placebo or pre-study baseline.

[0117] Some aspects of the method of treatment herein are to administer to the subject an amount of a non-selective mGluR network activator effective to reduce the ADHD rating scale score or Vanderbilt ADHD score by at least 25%, for example, at least 30% or at least 35% or at least 40% in a majority of clinical trial subjects after a certain treatment period, for example, 1, 2, 3, 4 or 5 weeks.In such an embodiment, the amount of administration can be selected, for example, based on clinical results showing that the amount has produced such results in a majority of clinical patients previously evaluated.For example, if the subject to be treated is a pediatric subject, the therapeutic amount can be selected based on the achievement of such results in a majority of patients in a pediatric clinical trial.

[0118] The Clinical Global Impression scale (CGI) is a widely used assessment instrument in psychiatry and a common secondary efficacy measure in ADHD clinical trials. The CGI scale generally asks clinicians to provide a global assessment of a patient's functioning, symptoms, and adverse events based on the clinician's experience with ADHD patients. The CGI scale has two components: CGI-S (Clinical Global Impression-Severity; a measure of illness severity) and CGI-I (Clinical Global Impression-Improvement; a measure of symptoms). Both scales range from 1 to 7. The CGI-S scale ranges from 1 (normal) to 3 (mild illness), 4 (moderate illness), 5 (marked illness), 6 (severe illness), and 7 (very severe impairment). The CGI-I scale ranges from 1 (marked improvement), 2 (moderate improvement), 3 (mild improvement), 4 (unchanged), 5 (mild worsening), 6 (moderate worsening), and 7 (severe worsening). Generally, subjects with a CGI-I score of 1 or 2 compared to baseline or placebo level are considered to be responders to treatment regimen.For example, in some cases, responders to a dosing regimen can show at least 25%, for example at least 30%, at least 35%, or at least 40% reduction in ADHD score or Vanderbilt ADHD score, and either a CGI-I score of 1 or 2 after a certain treatment period, for example, 1, 2, 3, 4, or 5 weeks.In some cases, responders can show a change in CGI-I, for example, 1 to 2 points, after 1, 2, 3, 4, or 5 weeks.In some cases, responders can show a CGI-S score of 1 or 2 or 3 after 1, 2, 3, 4, or 5 weeks.

[0119] In some embodiments of the methods herein, the amount of non-selective mGluR activator administered to a subject is selected based on the ability of that amount to produce a CGI-I score of 1 or 2 in a majority of subjects in a clinical trial, e.g., a clinical trial of similar subjects. Thus, for example, if a pediatric clinical trial reveals that a particular amount of activator produces a CGI-I score of 1 or 2 in a majority of patients in that trial after a particular period of time, that amount can be selected for administration to another pediatric subject as a therapeutic dose. Similarly, in some embodiments, the amount of non-selective mGluR activator administered to a subject is selected based on the amount that produces at least a 25%, e.g., at least a 35%, at least a 35%, or at least a 40% reduction in Vanderbilt ADHD score in a clinical trial of similar subjects. In some embodiments, the amount is selected for administration based on the amount that achieves a CGI-S score of 1-3, e.g., 1-2, in the subject after a treatment period. In some cases, an amount is selected for administration that produces a combination of these effects in a majority of clinical trial subjects.

[0120] The Persistent Outcome Measures of Performance (PERMP)-Math is an individualized mathematics test that can be administered to patients periodically while on and off medication for ADHD. It can be used, for example, to monitor academic performance in laboratory settings.

[0121] Typically, the PERMP exam contains 5 pages of 400 questions that subjects are instructed to work on for 10 minutes. Subjects may first be given a pre-test to determine their level of mathematical ability. Subjects are instructed to answer as many questions as they can in 10 minutes, and the exam is typically scored on a 0-800 scale based on the number of questions they work on in the time frame and the number of questions they answer correctly. Subjects take different versions of the exam at each location.

[0122] The Quotient ADHD score uses a medical device to measure hyperactivity, attention, and impulsivity in patients with ADHD. The Quotient ADHD tool uses motion tracking technology to track a patient's minute movements while they complete a 15-20 minute computerized test. After a patient completes the test, patterns of movement, accuracy of responses, and fluctuations in attention states can be analyzed.

[0123] Actigraphy is the non-invasive monitoring of a person's rest / activity cycle using an actigraph worn by the patient to record body movement. Actigraphs may be worn while at school, for example, to measure activity levels. Actigraphy analysis can measure changes in sleep and hyperactivity that may be seen with treatment of AHDH.

[0124] Additional questionnaires may be used by clinicians to assess comorbid symptoms, such as anger control and disruptive behavior, as well as to assess comorbid medical conditions.

[0125] X.Manufactured products In some embodiments, the invention includes articles of manufacture that can be used in the methods and treatments described herein. In one embodiment, the article of manufacture is a solid support or microarray for use in detecting genetic alterations in some or all of the mGluR network genes (i.e., Tiers 1-3) listed in Figures 1-3. In some embodiments, genes in multiple Tiers are evaluated within the same solid support or microarray. In some embodiments, certain mGluR network genes are excluded. In some embodiments, GRM genes are excluded.

[0126] Thus, for example, in some embodiments where mGluR network genes are assayed to determine whether one or more of said genes have a genetic alteration, such as a CNV, a solid support or microarray, e.g., a chip, is used that contains suitable probes for determining the presence of a genetic alteration in 10, 20, 30, 40, 50, 60, 70 or all of the Tier 1 genes. In some embodiments, the solid support or microarray may also include suitable probes for determining the presence of a genetic alteration in at least 10, 20, 30, 50, 100, 150 or all of the Tier 2 genes. In some embodiments, it may further include suitable probes for determining the presence of a genetic alteration in at least 10, 20, 50, 100, 200, 300, 400, 500 or all of the Tier 3 genes. For example, such solid supports, microarrays or chips can be used to determine the presence of genetic alterations, e.g., CNVs or SNVs, in the Tier 1, Tier 1+2, or Tier 1+2+3 mGluR gene networks as part of a method for treating patients with ADHD or 22q deletions and / or duplications.

[0127] In some embodiments, the product is a probe set for mGluR network genes of interest from Tier 1, 2 and / or 3. In some embodiments, the probes are labeled. In certain embodiments, the labels are not naturally occurring. Similarly, probe sets can be manufactured for determining the presence of genetic alterations in 10, 20, 30, 40, 50, 60, 70 or all Tier 1 genes. In some embodiments, probes can be manufactured for determining the presence of genetic alterations in at least 10, 20, 30, 50, 100, 150 or all Tier 2 genes. In some embodiments, the probes can further include those for determining the presence of genetic alterations in at least 10, 20, 50, 100, 200, 300, 400, 500 or all Tier 3 genes. These various probe sets can be used in methods to determine the presence of genetic alterations, e.g., CNVs or SNVs, in the Tier 1, Tier 1+2, or Tier 1+2+3 mGluR gene network as part of a method of treating a patient with ADHD or a 22q deletion and / or duplication. EXAMPLES

[0128] Example 1: Treatment of ADHD patients with CNVs in mGluR network genes with NFC-1 (fasoracetam monohydrate) An open-label Phase Ib clinical trial was initiated to investigate the safety, pharmacokinetics, and efficacy of NFC-1 (fasoracetam monohydrate) in adolescent subjects between the ages of 12 and 17 years, previously diagnosed with ADHD, who also have at least one genetic alteration in an mGluR network gene.

[0129] The study included 30 subjects between 12 and 17 years of age, of any origin or race, weight within the 5th and 95th percentiles for their age, and otherwise determined to be in good medical health. Subjects had ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) and a Vanderbilt ADHD score of 16 or greater at baseline (as assessed by parents or teachers), and may or may not have been receiving traditional ADHD treatment. Subjects were genotyped and included in the trial if they had at least one genetic alteration in the form of at least one copy number variation (deletion or duplication) in an mGluR network gene that may disrupt the function of the gene. Seventeen of the 30 subjects had CNVs in tier 1 mGluR network genes, while seven subjects had CNVs in Tier 2 genes and six had CNVs in Tier 3 genes. Two of the 30 ADHD subjects in the trial also had 22q syndrome, one had 22q deletion syndrome, and one had 22q duplication syndrome. Several study subjects showed evidence of a comorbid phenotype in addition to ADHD at enrollment, e.g., anxiety, mood disorder, sleep disorder such as insomnia, depression, ODD, or conduct disorder, based on results on items 19-47 of the Vanderbilt Questionnaire.

[0130] Exclusion criteria included subjects who, in the opinion of the investigator, suffered from any clinically significant mental or physical illness that might confound the results of the study or prevent completion of the study; subjects who were pregnant or breastfeeding; subjects who had a history of drug abuse, tested positive for illicit drugs; subjects who consumed alcoholic beverages; or subjects who otherwise gave the investigator concerns regarding their compliance or suitability.

[0131] NFC-1 capsules containing either 50 mg or 200 mg of fasoracetam monohydrate as the active ingredient, and placebo capsules containing microcellulose were used in the study. The study design included telephone screening (1 day), enrollment period (1 to 2 days), washout period (1-14 days) for subjects currently treated with ADHD medications, pharmacokinetic (PK) evaluation (2 days), followed by a dose titration period (35 days), and a follow-up visit approximately 4 weeks after the last dose, for a maximum of 127 days. All ADHD medications were discontinued during the pre-study washout period. The washout period for stimulants was 2-3 days, and the washout period for atomoxetine or noradrenergic agonists was 10-12 days. No new ADHD medications were started during the study.

[0132] All subjects participated in PK evaluation. For the PK portion of the study, subjects received a single dose of 50 to 800 mg of NFC-1 and blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after dosing. Thirty subjects were divided into five groups of six subjects for PK and initial safety evaluation, with each group receiving a different dose range of 50, 100, 200, 400, or 800 mg. PK parameters Cmax, Tmax, and AUC0-24h were calculated based on serum NFC-1 levels.

[0133] The PK and initial safety assessments were followed by the dose escalation phase of the study, which lasted for 5 weeks. During the first week, all subjects received a placebo capsule twice daily. After 1 week of placebo treatment, patients were initiated on 1 week of 50 mg bid NFC-1. If the safety and response data from the previous dose level of fasoracetam were adequate, the subject's dose was increased to the next higher dose (100, 200, or 400 mg). Subjects who tolerated and responded to the drug at the 50 mg bid dose were to remain at that level for the remaining 3 weeks of the study. Subjects who tolerated but showed a lack of response or partial response to the 50 mg bid dose were to be increased to the next higher dose of 100 mg for the subsequent week. Subjects who tolerated 100 mg but showed a lack of response or a partial response were to be increased to a 200 mg dose for the following week, while subjects who both tolerated and responded to 100 mg were to remain on 100 mg bid for the remainder of the study. Similarly, subjects who were increased to the 200 mg dose and both tolerated and responded were to remain on 200 mg for the final week of the study, while subjects who tolerated but showed a lack of response or a partial response were changed to a 400 mg dose for the final week. Of the 30 study subjects, 3 received a maximum dose of 100 mg, 9 received a maximum dose of 200 mg, and the remaining 18 received a maximum dose of 400 mg.

[0134] All efficacy assessments except actigraphy were performed at study enrollment ("Enrollment Baseline"), once a week during the placebo week ("Week 1" or "Placebo Baseline"), and again during each of the four weeks of NFC-1 treatment, including actigraphy. These efficacy measures included Vanderbilt Inventory items 1-18, which assess symptoms related to inattention and hyperactivity-impulsivity, and additional questions 19-47 of the Vanderbilt Inventory (administered by parents), which assess other behavioral symptoms; actigraphy for quantitative measurement of activity; the Quotient® ADHD test for objective measurement of minimal movements and attentional shifts; the PERMP-Math test; and the CGI-I and CGI-S for assessment of global functioning. Prior to receiving the PK evaluation dose, subjects returned to the clinic to complete the PERMP-Math test, undergo actigraphy (set to run at the time of first placebo dose 2 days later), and undergo a complete physical examination including vital signs and weight, blood and urine collections, and for female subjects, a pregnancy test. During the 5-week placebo and dose-escalation phase of the study, subjects returned to the clinic each weekend to complete the Quotient® and PERMP-Math test, undergo actigraphy, Vanderbilt and BRIEF measurements (administered by parent), and undergo a complete physical examination including vital signs and weight, blood and urine collections, and for female subjects, a pregnancy test.

[0135] Data analysis considered subjects overall and by genetic tier (1, 2 or 3) or by genetic tier group (1 and 2 vs. 3). Subject number, maximum dose administered, age, genetic tier, and placebo baseline (i.e., week 1) and final (i.e., week 5) CGI-I, Vanderbilt and PERMP results for all 30 subjects are shown in Table 1 below. Subjects 110 and 127 suffer from both ADHD and 22q deletion and / or duplication syndrome. Thirteen subjects had a diagnosis of ODD, and one of these subjects did not complete the study. Thus, 12 subjects, numbered 102, 103, 108, 111, 112, 114, 117, 122, 125, 126, 128 and 130, have both ADHD and ODD and completed the study.

[0136] See Table 1 on the next page (the remainder of the page is intentionally left blank). TIFF2024164036000002.tif248170TIFF2024164036000003.tif249170

[0137] Based on Table 1, the mean initial CGI-I score and mean final CGI-I score for the 30 subjects was 3.67 (placebo baseline) at week 1 and 2.27 at week 5, with a mean improvement of 1.4. This generally indicates that subjects had, on average, a "moderate improvement" or "marked improvement" (CGI-I of 1 or 2) by the end of the dose escalation phase of treatment. The change in CGI-I score from enrollment baseline to week 5 for the 30 study subjects is summarized in Tables 2(a)-(c) below. As shown below, the mean improvement in CGI-I score for all subjects was 1.57, which corresponds to a "moderate improvement" to "marked improvement" status. Genetic Tier 1 and 2 subjects improved more than Tier 3 subjects, with P=0.0402. Table 2(a), (b), (c): CGI-I at week 5 compared to CGI-I at pre-study enrollment baseline for all subjects, by genetic tier and by tier group. TIFF2024164036000004.tif33170TIFF2024164036000005.tif42170TIFF2024164036000006.tif38170

[0138] CGI-S scores decreased from a mean of approximately 4 to a mean of approximately 3 from enrollment to week 5. The change in CGI-S from enrollment baseline to week 5 is shown below in Table 2(d)-(f). The mean change was approximately 1 across all subjects. TIFF2024164036000007.tif32170TIFF2024164036000008.tif42170TIFF2024164036000009.tif38170

[0139] Table 3 provides an analysis of the percentage of subjects in the total study population and genetic tiers who were considered responders, i.e., had a CGI-I score of 1 or 2 at each week of the dose escalation phase of the study. These data are also shown graphically in Figure 4. As shown in Table 3 and Figure 4, at week 4, approximately 55% of subjects were considered responders based on CGI-I score, including 56% of Tier 1 and 50% of Tier 2, while none of the 6 Tier 3 subjects were significant responders. By week 5 of dose escalation, 83% of study subjects were considered responders based on CGI-I score, including 81% and 86% of genetic Tiers 1 and 2, and 40% of genetic Tier 3. In the table below, "N" represents the number of subjects who had a measured CGI-I score, and "%" indicates the percentage of subjects who showed a CGI-I score of 1 or 2 compared to the genetic tier group or compared to the total study population (in the "Total" row of the table). TIFF2024164036000010.tif54170

[0140] The mean Vanderbilt ADHD scores (and standard errors) for each week of the study are shown in Table 4. These values ​​were calculated using a repeated measures analysis of variance (RMANOVA). This analysis corrects for within-individual variance in the repeated efficacy measures to more easily detect changes that may be attributable to the effect of the study. Note that the standard errors are the same for each of the weekly values ​​in Table 4 below, as they were estimated from the RMANOVA statistical model. As Table 4 shows, the mean Vanderbilt ADHD scores decreased each week from placebo baseline (week 1) to week 5. The within-patient changes were also statistically significant (p<0.001), supporting the conclusion that the Vanderbilt scores for this population decreased over time with participation in this study. TIFF2024164036000011.tif31170

[0141] Table 5 below presents the number and percentage of subjects who showed improvement in Vanderbilt ADHD score each week compared to either the pre-study baseline or the placebo baseline (week 1) for both genetic tier and the total study population. These results are also shown graphically in Figures 5a and 5b. A reduction of at least 25% in the Vanderbilt ADHD score is considered responsive and improved, and a reduction of at least 40% in the score is considered a strong improvement. TIFF2024164036000012.tif81170

[0142] As shown in Table 5 and Figure 5, 78% of subjects were responsive to treatment at week 5 compared to baseline based on Vanderbilt ADHD score, and an additional 52% were responsive at week 5 compared to placebo baseline. A higher percentage of subjects were responsive in genetic Tiers 1 and 2 compared to subjects in Tier 3. The percentage of patients who were strongly improved at week 5 compared to study baseline and placebo baseline is shown graphically in Figures 7a and 7b and further shown in Table 6. As can be seen from these figures and tables, 52% of subjects were strongly improved compared to baseline, and an additional 37% were strongly improved compared to placebo baseline, all of which were in genetic Tiers 1 and 2. TIFF2024164036000013.tif81170

[0143] As shown in Table 1, 18 of the 30 subjects in this study completed the dose escalation to 400 mg bid at week 5. The percentages of the 18 subjects showing improvement (i.e., response) and strong improvement in Vanderbilt ADHD scores at week 5 compared to pre-study baseline or week 1 placebo baseline are shown in Tables 7 and 8 and Figures 7 and 8, respectively. TIFF2024164036000014.tif87170TIFF2024164036000015.tif87170

[0144] Based on the data in Table 1, the mean change in PERMP score from pre-study baseline to week 5 was minus 3.43. When analyzed based on genetic tier, there was no significant difference in the overall mean change. Those in Tier 1 and 2 had a mean change in PERMP of minus 3.0 (mean of minus 3.35 for Tier 1 and minus 2.14 for Tier 2), while those in Tier 3 had a mean change of minus 5.17. The PERMP scores showed little change, which may be due, at least in part, to uncontrolled environmental factors due to the way the PERMP test was conducted. The test was conducted during a clinic visit and therefore not necessarily at the same time post-dose or at the same time every week for each subject. The test was also conducted during a clinic visit and not in a classroom. Thus, for example, distractions in the clinic waiting room may vary from visit to visit and were not controlled for.

[0145] Overall, parent-assessed Vanderbilt ADHD scores indicate that approximately 75-80% of subjects had at least a 25% reduction in scores at the end of the dose-titration phase of the study (i.e., at the end of week 5) compared to pre-study baseline. Approximately 63% of subjects showed strong improvement, i.e., at least a 40% change in Vanderbilt ADHD score. In addition, approximately 80-85% of subjects showed a CGI-I score of 1 or 2 at week 5, indicating that they had moderate or marked improvement by week 5 of the study compared to pre-study baseline. PERMP results did not show significant changes over the course of the study.

[0146] Results from actigraphy showed a significant reduction in moderate / vigorous movement bursts at the highest dose of NFC-1 (400 mg bid) compared to placebo (P<0.001). As shown in Figures 9a-9c, the observed declines in moderate / vigorous physical activity (MVPA) from week 1 (placebo) to week 5 for gene Tier-1 (Figure 9a), gene Tier-2 (Figure 9b), and gene Tier-3 (Figure 9c) were most pronounced in the 400 mg bid dose group.

[0147] Results from the QUOTIENT® ADHD study showed high noise levels. Nevertheless, as shown in Figure 10, clinical trial subjects in the Tier-1 genetic group had significant improvements in the test measures of inattention between week 1 (placebo) and week 5 (400 mg twice daily) as seen by a reduction in inattention in the Tier-1 group from normalized inattention values ​​of just over 100 to approximately 90 between week 4 and week 5 of dose escalation (P<0.05).

[0148] Subjects 110 and 127 in this study, both genetic Tier 1, have either a deletion or duplication in 22q that includes the RANBP1 gene, an interactor of mGluR3, and therefore have 22q syndrome in addition to a diagnosis of ADHD. Both subjects completed the full dose titration to 400 mg bid by week 5 of the study. Subject 110 had an IQ measurement of 91 prior to the study, and showed a 1 point improvement in the CGI-S indicating a change from moderate to mild disease by week 5 compared to week 1, and a CGI-I of 2 indicating a moderate improvement. Subject 110 also showed a 5 point change in Vanderbilt ADHD score from 22 to 17 by week 5 compared to week 1.

[0149] Subject 127 had an IQ measurement of 65 prior to the study, a CGI-S of 6 at week 1 indicating severe illness, and a 2 point improvement in the CGI-S to 4 indicating moderate illness by week 3, which he maintained all the way through week 5. Subject 127, like subject 110, also had a CGI-I of 2, indicating that in the clinician's opinion, this subject had moderate improvement by the end of dose escalation. Subject 127 also showed a strong reduction in Vanderbilt ADHD score from 44 to 25 at week 3, but did not achieve a fourth Vanderbilt ADHD score, and had a score of 33 at week 5. The full CGI, Vanderbilt ADHD and PERMP results for subjects 110 and 127 are shown in the table below. Both of these 22q subjects had improvements in 22q syndrome while taking NFC-1, including improvements in social interaction / communication disorders, lack of social participation, anxiety, mood swings, depression, inattention, hyperactivity, and decreased performance in school (and life skills in general). Thus, NFC-1 is useful in 22q syndrome patients. TIFF2024164036000016.tif91170

[0150] Thirteen of the 30 subjects enrolled in the trial showed symptoms of ODD as well as ADHD. Subjects were identified as having ODD based on the K-SADS-P V6 administered at screening and the Vanderbilt scores for ODD at screening and week 1 (scores of 2 or 3 on at least 4 of the 8 Vanderbilt items assessing ODD, i.e. items 19 to 26). By the end of the dose escalation phase of the trial at week 5, 4 of the 12 subjects (numbers 108, 117, 125, and 128) no longer met the screening criteria for ODD. 4 of the remaining 8 showed an improvement of 2 or more points from week 1 to week 5.

[0151] Subject 108, who had enrollment and week 1 placebo baseline scores ("Vanderbilt ODD scores") for items 19-26 of 23 and 19, respectively, out of a maximum of 24, had a score of 7 out of 24 by the end of week 5, with no individual scores above 2. Subject 117 had a placebo baseline Vanderbilt ODD score of 19 and a week 5 score of 8, with only one question scored 2. Subject 128 had enrollment and placebo Vanderbilt ODD baseline scores of 23 and 24, respectively, which had decreased to 8 / 24 by week 5, with no individual scores above 1. In addition, by the end of week 5, the Vanderbilt ODD scores for all 13 subjects improved from week 1 to week 5. Eleven of the 13 subjects showed an improvement of at least 3 points, and six of the 13 showed an improvement of at least 8 points from week 1 to week 5.

[0152] In addition, three of the 13 subjects who screened positive for ODD at enrollment were receiving antipsychotic treatment at enrollment and throughout the study. Subjects 111 and 126 were receiving Abilify® (aripiprazole), while subject 122 was receiving Risperdal® (risperidone). Nevertheless, the Vanderbilt ODD scores for each of these three subjects improved between weeks 1 and 5.

[0153] One subject (number 130) who screened positive for ODD also screened positive for conduct disorder (CD) based on a score of 2 or 3 for 3 of 15 behaviors assessed by items 27-40 of the Vanderbilt Questionnaire at enrollment and again at week 1. By week 5, this individual's Vanderbilt ODD score improved by 3 points, from 24 / 24 at week 1 to 21 / 24, and his Vanderbilt CD score improved by 4 points, from 16 / 16 at week 1 to 12 / 16 at week 5.

[0154] Certain subjects in this study also showed other comorbidity phenotypes, such as anxiety, depression, mood disorders, and sleep disorders, such as insomnia, according to the information recorded at enrollment and at week 1. Two subjects had a maximum score of 3 on two of the three Vanderbilt items 41, 42, and 47 for anxiety at enrollment. At week 5, these subjects scored 3 on all three items. One of these subjects also scored 3 on three of the four Vanderbilt items for depression (items 43-46) at enrollment and 3 on all four items at week 1. By week 5, this subject scored 1 or 2 on all four items. This indicates an improvement in depression symptoms.

[0155] The results of the short questionnaire were also analyzed for change in anxiety / mood scores for all 30 subjects. The short questionnaire administered by the parents included a set of items related to anxiety and mood, specifically: 1. Overreacting to small problems; 6. Feeling upset by new situations; 7. Sudden rage; 12. Being upset by changes in plans; 13. Feeling anxious about changing teachers / classes; 20. Tearful; 23. Resistance to changes in usual routines, foods, or plans; 25. Emotional outbursts for almost no reason; 26. Frequent mood changes; 30. Difficulty adapting to new situations; 45. Reacts more strongly to situations than other children; 50. Mood is easily influenced by situations; 62. Outbursts of anger and tears that are intense but end suddenly; 64. Small events provoke large reactions; and 70. I get upset very easily.

[0156] The answers to these questions were scored as "never," "sometimes," or "often." This simple test was administered at enrollment and again after each dose-escalation treatment week from placebo week to week 5. The total scores for all 30 subjects for each of the above questions were summed for enrollment and week 5, with 1 point given for each score of "never" or "often." The total score for "never" for all subjects for all questions at enrollment was found to be 125 and 191 at week 5, indicating a trend toward improvement. Similarly, the total score for "often" at enrollment was 154, while the total score for "often" at week 5 was 77. Again, this indicates a trend toward improvement in anxiety and mood symptoms.

[0157] Example 2: Phase 2 study of treatment with NFC-1 (fasoracetam monohydrate) in ADHD patients with CNVs in mGluR network genes A randomized, double-blind, placebo-controlled, parallel-group Phase 2 study will be conducted in ADHD subjects aged 12-17 years to compare the safety and efficacy of NFC-1 with that of placebo. Approximately 90 male and female subjects will be randomized to treatment with NFC-1 or placebo to obtain 80 subjects who complete the study as planned. Subjects will have ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) and Attention Deficit Hyperactivity Disorder Rating Scale, version 5 (ADHD RS-5) >28 at baseline and may or may not be receiving conventional ADHD treatment. Approximately 45 subjects will be in each treatment group.

[0158] On day 1, subjects will be randomly assigned to receive either NFC-1 or placebo, and will begin receiving the product at a dose of 100 mg twice daily on day 1. Over the course of 4 weeks of treatment, dosing will be optimized to 100 mg, 200 mg, or 300 mg twice daily as needed based on clinical response and tolerability (dose optimization phase). If subjects tolerate the dose well, they will be maintained on that dose for an additional 2 weeks (dose maintenance phase), at which time the primary efficacy and tolerability assessment will be performed. Efficacy will be assessed by ADHD Rating Scale scores, CGI-I, CGI-S, Child and Adolescent Sleep Hygiene Scale (ASHS), and Childhood Anxiety-Related Emotional Disorder Scale (SCRED). The ASHS is a self-assessment questionnaire that assesses sleep habits that are theoretically important for optimal sleep in adolescents aged 12 years and older. It assesses physiological (e.g., nighttime caffeine intake), cognitive (e.g., thinking before bed about things that need to be done), emotional (e.g., going to bed feeling agitated), sleep environment (falling asleep with the lights on), sleep stability (e.g., different bedtime / wake-up time patterns on weekdays and weekends), substance use (e.g., nighttime alcohol use), daytime sleep (e.g., napping), and having a sleep onset ritual. The SCARED is a child self-administered instrument for ages 18 used to screen for childhood anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, panic disorder, and social phobia. In addition, it assesses symptoms related to school phobia. The SCARED consists of 41 items and 5 factors that parallel the DSM-IV classification of anxiety disorders. The scale has good internal consistency, test-retest reliability, and discriminant validity, and is sensitive to treatment response. Safety and adverse events will also be assessed during the study.

[0159] Example 3: A 12-Week, Double-Blind, Placebo-Controlled, Randomized Treatment Withdrawal Study of NFC-1 (Fasoracetam Monohydrate) in Subjects With 22q11.2 Deletion Disorder A 12-week Phase I trial will be conducted in subjects aged 12-17 years with 22q11.2 Deletion Syndrome (22q11.2DS) with comorbid neuropsychiatric disorders: ADHD and / or Autism Spectrum Disorder (ASD) to evaluate the safety and tolerability of a twice-daily oral dose of NFC-1. There will be a 5-week open-label dose optimization followed by a 7-week double-blind, placebo-controlled, randomized withdrawal evaluation in subjects aged 12-17 years. Approximately 40 subjects will be enrolled, dose optimized, and maintained on NFC-1 for 5 weeks.

[0160] Doses will be administered orally twice daily and optimized to 50, 100, 200 or 400 mg twice daily as needed during the first 5 weeks. Response to treatment will be defined as achievement of significant improvement in symptoms as indicated by a CGI-I score of <3 and a CGI-S score of <4 after 5 weeks of dose optimization.

[0161] At the end of week 5, if a subject had a CGI-I score of <3 and a CGI-S of <4 (a responder), they will be randomized to NFC-1 or placebo for the 7-week off-treatment phase of the study. Subjects in the off-treatment phase will then be evaluated for sustained efficacy or treatment failure (defined as an increase of 2 or more points on the CGI-S compared to the score at the end of week 5) over the next 7 weeks. Subjects who experience relapse (defined as an increase of at least 2 points relative to the CGI-S score at the end of week 5) will discontinue treatment.

[0162] The efficacy and effectiveness of NFC-1 on individual symptoms will be evaluated using the CGI-I, CGI-S, ADHD Rating Scale score, Pediatric Anxiety Rating Scale (PARS), Aberrant Behavior Checklist (ABC), and Childhood Autism Rating Scale for Mental Retardation 2 (CARSTM-2). The ABC test is a symptom checklist for evaluating problem behaviors in individuals with mental retardation. It includes a clinical assessment of the person's mental retardation, medical status, and degree of current medical condition, and includes an assessment of 58 specific symptoms performed by a parent, educator, psychologist, nurse, or physician knowledgeable about the subject. The behaviors evaluated include irritability / agitation, lethargy / withdrawal, stereotypic behavior, hyperactivity / noncompliance, and inappropriate speech. The PARS is a clinician-rated scale of anxiety symptoms in pediatric subjects consisting of a list of 50 anxiety-related disorders. Each of the 50 items is scored on a scale of 0 to 5, with 0 indicating no symptoms and 5 indicating severe symptoms. The CARSTM-2 rating scale is a question-based scale that helps evaluate childhood autism symptoms. The scale gives a score of 1 for normal, 2 for mild abnormality, 3 for moderate abnormality, and 4 for severe abnormality. The questionnaire assesses 15 items, including interpersonal relationships, imitation, emotional response, adaptation to change, visual response, listening response, fearfulness / nervousness, verbal and nonverbal communication, and activity level. Scores range from 15 to 60 depending on the score (1-4) for each item.

[0163] Example 4: Blinded Screening of Biorepository Samples for mGluR Network CNVs and Association to ADHD Diagnosis A total of 3445 biorepository samples from the Center for Applied Genomics biorepository at Children's Hospital of Philadelphia with psychiatric evaluation records were studied to determine the number of samples with one or more CNVs in Tier 1 or 2 mGluR network genes. The genotyper / analyst performed the CNV analysis but was blinded to the subject's psychiatric diagnosis. The purpose of this study was to estimate the predictive value of CNVs in mGluR network genes by analyzing the number of CNV-positive samples that were previously confirmed to have ADHD from the accompanying psychiatric evaluation data. 155 of the 3445 samples, or about 4.5%, were confirmed to have at least one CNV in Tier 1 or Tier 2 mGluR network genes. 138 of the 155 with CNVs in Tier 1 or 2 mGluR network genes were previously confirmed to have ADHD, while the remainder had no such records. In addition, about 60% of the 138 ADHD subjects also had comorbid anxiety symptoms.

[0164] Of the 17 subjects with no records, we were able to successfully contact the families of 14 and asked questions regarding whether the subject had been diagnosed with ADHD. Thirteen of the 14 families confirmed that the subject had indeed been diagnosed with ADHD. Note that one of the 13 had Down's syndrome and was considered negative for ADHD in this study. Overall, therefore, of the 155 subjects who had at least one CNV in an mGluR network gene, 138 + 12 subjects (150), or about 97%, were also diagnosed with ADHD, while data were missing for the remaining three. These data indicate that the presence of a CNV in a Tier 1 or 2 mGluR network gene may be a strong indicator of ADHD in pediatric subjects.

[0165] Example 5: Investigation of phenotypes associated with mGluR network CNVs A total of 1,000 ADHD patients aged 6-17 years were enrolled in the trial to examine phenotypes that may be associated with CNVs in Tier 1 or 2 mGluR network genes. Saliva samples for DNA samples were collected by the study site. Each DNA sample was then subjected to DNA extraction, gene sequencing, and DNA biobanking.

[0166] Genetic sequencing results, together with medical history, were used to assess genotype (based on gene sequencing) and phenotype (based on interviews conducted by clinicians and the subject's parent / guardian).Subjects had ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V).

[0167] A single clinician blinded to the genotype data asked the parent or legal guardian of the subject a series of questions regarding possible behavioral or health phenotypes. For each individual phenotype, the parent / guardian was asked "Is this a current concern?" and a yes or no answer was collected. The clinician determined the frequency of yes or no responses to generate phenotype data.

[0168] This study found that the prevalence of anger control as a current concern was 58.9% in ADHD subjects with Tier 1 or 2 mGluR network gene CNVs, but only 47.4% in ADHD subjects without such mGluR network gene CNVs. This difference was statistically significant (odds ratio of 1.59, P=0.003). This odds ratio, which is greater than 1, implies a higher prevalence of anger control as a current concern in ADHD subjects with Tier 1 or 2 mGluR network gene CNVs compared to those without such CNVs.

[0169] The prevalence of disruptive behavior as a current patient concern was 57.1% in ADHD subjects with Tier 1 or 2 mGluR network gene CNVs and 43.9% in ADHD subjects without such mGluR network gene CNVs. This difference was also statistically significant (odds ratio of 1.70, P<0.001). This difference indicates a higher prevalence of current disruptive behavior concerns in ADHD subjects who also have mGluR network gene mutations versus those without mutations.

[0170] Example 6: Copy number variation of mGluR network genes in ADHD subjects with comorbid disorders Samples from 2707 pediatric subjects (mean age 10-10.5 years) known to have ADHD were genotyped using the 550 / 610 Illumina chip to determine whether they had one or more CNVs in Tier 1 or Tier 2 genes. The 2707 subjects included 759 females and 1778 males of African American or Caucasian ethnicity (1063 and 1483, respectively). 430 (16.9%) of the 2707 subjects had at least one CNV in an mGluR Tier 1 or Tier 2 gene.

[0171] The records of the 2707 subjects were also reviewed to determine whether they were diagnosed with comorbidities according to the World Health Organization International Classification of Diseases, Ninth Revision (ICD-9). Of the 2707 subjects, 1902 (approximately 70%) had comorbidities, while 805 did not. Of these 1902 subjects with comorbidities, approximately 30% had more than one comorbidity, approximately 20% had two or more, while a small percentage had a greater number of comorbidities.

[0172] The most prevalent comorbidities that were present in more than 100 subjects each are listed in Table 10. This table lists the comorbidities by ICD-9 code and provides the number of cases among the 2707 subjects (column titled "N") and the name for each comorbid condition or disorder. TIFF2024164036000017.tif113170

[0173] The comorbidities in Table 10 tend to cluster into a few distinct groups: anxiety, depression or mood related disorders; high prevalence developmental disorders; low prevalence developmental disorders; and autism and related disorders.

[0174] The phenotypic and comorbidity data were then combined to determine how many of the subjects with Tier 1 or 2 mGluR network gene CNVs also had comorbidities. It was found that 316 of the subjects with such CNVs (approximately 18% of CNV-positive subjects or 12% of all subjects) also had at least one comorbidity, while 114 of the subjects without Tier 1 or 2 mGluR network gene CNVs (approximately 15% of CNV-negative subjects or 4% of all subjects) also had at least one comorbidity. This difference had a P value of 0.118. Thus, overall, comorbidities tended to be more prevalent in CNV-positive subjects than in CNV-negative subjects. There was a highly significant correlation between mGluR CNVs and ADHD comorbidity when only subjects identified as Caucasian were considered. Specifically, 218 of 1483 subjects had at least one CNV in a Tier 1 or 2 mGluR network gene, and of these 218 subjects, 169 also had a comorbidity, whereas 49 did not. This difference had a P-value of 0.004.

[0175] The above specification is believed to be sufficient to enable one skilled in the art to practice the embodiments. The above description and examples detail certain embodiments and explain the best mode contemplated by the inventors. However, no matter how detailed the foregoing may appear in the text, it will be understood that the embodiments can be practiced in many ways and that the embodiments should be construed in accordance with the appended claims and any equivalents thereof.

[0176] The term about as used herein refers to numerical values, including, for example, integers, fractions, and percentages, whether or not expressly indicated. The term about generally refers to a range of numbers (e.g., + / - 5-10% of the recited range) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). When terms such as at least and about precede a list of numerical values ​​or ranges, these terms modify all of the values ​​or ranges given in that list. In some cases, the term about may include numerical values ​​that are rounded to the nearest significant figure.

Claims

1. A method for treating attention deficit hyperactivity disorder (ADHD) in a subject, comprising administering to the subject a therapeutically effective amount of a nonselective metabotropic glutamate receptor (mGluR) activator, thereby treating the ADHD.

2. 1. A method for treating ADHD in a subject, comprising administering a therapeutically effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject having at least one genetic alteration in an mGluR network gene, thereby treating the ADHD.

3. 1. A method of treating ADHD in a subject, comprising: Administering a non-selective metabotropic glutamate receptor (mGluR) activator to subjects with ADHD in an amount effective to result in a Clinical Global Impression-Improvement (CGI-I) score of 1 or 2 after at least 4 weeks of treatment and / or at least a 25%, e.g., at least a 30%, at least a 35%, or at least a 40% improvement in ADHD rating scale score after at least 4 weeks of treatment in a majority of subjects in at least one clinical trial. The method includes:

4. 4. The method of claim 1, wherein the subject has at least one genetic alteration, such as a point mutation, an insertion, a deletion, or a copy number variation (CNV), in an mGluR network gene.

5. The method of claim 4, wherein at least one genetic alteration is a CNV.

6. The method of claim 5 , wherein the CNV is a deletion or duplication.

7. 7. The method of any one of claims 2, 4, 5 or 6, wherein the subject has a genetic alteration in at least two mGluR network genes.

8. 8. The method of any one of claims 1 to 7, wherein the subject is a child or adolescent subject, for example a subject aged between 5 and 17 years, between 8 and 17 years, between 5 and 12 years, between 5 and 8 years, between 8 and 12 years, or between 12 and 17 years.

9. 8. The method of any one of claims 1 to 7, wherein the subject is an adult.

10. 10. The method of any one of claims 1 to 9, wherein the non-selective mGluR activator is fasoracetam, e.g. fasoracetam monohydrate.

11. 11. The method of claim 10, wherein the fasoracetam is administered in a dose of 50-400 mg, such as 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, said dose being administered once, twice or three times daily.

12. 12. The method of claim 11, wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg or 400 mg twice daily, for example 100-200 mg twice daily, or 200-400 mg twice daily.

13. The activator may be used in combination with a stimulant, such as methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, or lisdexamfetamine, and / or in combination with a non-stimulant, such as atomoxetine, clonidine, or guanfacine, and / or in combination with an antidepressant, such as fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, or monoamine oxidase inhibitors, and / or in combination with an antianxiety drug, such as barbiturates, pregabalin, or benzodiazepines (chlordiazepoxide, clorazepate, 13. The method of any one of claims 1 to 12, wherein the medicament is administered in combination with a medicament such as azepam, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam or midazolam, and / or in combination with an antipsychotic, such as aripiprazole or risperidone, and / or in combination with a beta-blocker, such as acebutolol, atenolol, betaxolol, bisoprolol, esmolol, nebivolol, metoprolol, cartelol, penbutolol, pindolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, propranolol, sotalol or timolol.

14. 14. The method of any one of claims 1 to 13, wherein the activator is administered in combination with a non-pharmacological therapy, such as brain stimulation, such as vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetoconvulsive therapy, and / or deep brain stimulation.

15. 15. The method of any one of claims 1 to 14, wherein the subject has, in addition to ADHD, at least one of oppositional defiant disorder (ODD), 22q deletion / duplication syndrome, anxiety disorder, mood disorder, phobia, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder.

16. 15. The method of any one of claims 1 to 14, wherein the subject does not have at least one of oppositional defiant disorder (ODD), 22q deletion / duplication syndrome, anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, mood disorder, phobia, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder.

17. 17. The method of claim 16, wherein the subject does not have any of ODD, 22q deletion / duplication syndrome, anxiety disorder, mood disorder, phobia, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, and movement disorder.

18. 16. The method of any one of claims 1 to 15, wherein the subject has ODD.

19. 20. The method of claim 18, wherein ODD in a subject is treated by reducing symptoms of, for example, anger and irritability, argumentative and defiant behavior, and / or vindictiveness.

20. 20. The method of any one of claims 2 or 4 to 19, wherein the genetic variation is detected by a process comprising a genetic test comprising obtaining a sample from the subject, optionally isolating nucleic acid from the sample, optionally amplifying the nucleic acid and analyzing the nucleic acid for a genetic variation in at least one mGluR network gene, and the results of the genetic test are obtained prior to a first administration of the activator.

21. 21. The method of claim 20, wherein the genetic testing comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes.

22. 22. The method of claim 20 or claim 21, wherein the genetic testing comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes.

23. 23. The method of claim 20, 21 or 22, wherein the genetic testing comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

24. 24. The method of any one of claims 20 to 23, wherein the genetic test does not evaluate CNVs and SNVs of one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

25. 1. A method of treating attention deficit hyperactivity disorder (ADHD) in a subject comprising administering fasoracetam at a dose of 50-400 mg, for example 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, wherein said dose is administered to the subject once, twice or three times daily, thereby treating ADHD.

26. 26. The method of claim 25, wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg or 400 mg twice daily, for example 100-200 mg twice daily.

27. 27. The method of claim 25 or 26, wherein the ADHD subject has at least one genetic alteration, such as a point mutation, insertion, deletion, or copy number variation (CNV), in an mGluR network gene.

28. 28. The method of claim 27, wherein at least one genetic alteration is a CNV.

29. 29. The method of any one of claims 27 or 28, wherein the subject has a genetic alteration in at least two mGluR network genes.

30. 30. The method of any one of claims 25 to 29, wherein the subject is a child or adolescent subject, for example a subject aged between 5 and 17 years, between 8 and 17 years, between 5 and 12 years, between 5 and 8 years, between 8 and 12 years, or between 12 and 17 years.

31. 30. The method of any one of claims 25 to 29, wherein the subject is an adult subject.

32. The fasoracetam may be used in combination with stimulants such as methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine or lisdexamfetamine, and / or in combination with non-stimulants such as atomoxetine, clonidine or guanfacine, and / or in combination with antidepressants such as fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors or monoamine oxidase inhibitors, and / or in combination with antianxiety drugs such as barbiturates, pregabalin or benzodiazepines (chlordiazepoxide, clorazepate, 32. The method of any one of claims 25 to 31, wherein the agonist is administered in combination with a vasopressin-releasing agent, such as azepam, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam or midazolam, and / or in combination with an antipsychotic, such as aripiprazole or risperidone, and / or in combination with a beta-blocker, such as acebutolol, atenolol, betaxolol, bisoprolol, esmolol, nebivolol, metoprolol, cartelol, penbutolol, pindolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, propranolol, sotalol or timolol.

33. 33. The method of any one of claims 25 to 32, wherein the fasoracetam is administered in combination with a non-pharmacological therapy, such as brain stimulation, such as vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetoconvulsive therapy, and / or deep brain stimulation.

34. 34. The method of any one of claims 25 to 33, wherein the subject has, in addition to ADHD, at least one of oppositional defiant disorder (ODD), 22q deletion / duplication syndrome, anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, mood disorder, phobia, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder.

35. 34. The method of any one of claims 25 to 33, wherein the subject does not have at least one of oppositional defiant disorder (ODD), 22q deletion / duplication syndrome, anxiety disorder, mood disorder, phobia, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder.

36. 36. The method of claim 35, wherein the subject does not suffer from any of ODD, 22q deletion / duplication syndrome, anxiety disorder, mood disorder, phobia, conduct disorder, Tourette's syndrome, autism, anger control disorders, disruptive behavior, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorders, and movement disorders.

37. 36. The method of any one of claims 25 to 35, wherein the subject has ODD.

38. 38. The method of claim 37, wherein ODD in a subject is treated by reducing symptoms of, for example, anger and irritability, argumentative and defiant behavior, and / or vindictiveness.

39. 39. The method of any one of claims 25 to 38, wherein the genetic variation is detected by a process comprising a genetic test comprising obtaining a sample from the subject, optionally isolating nucleic acid from the sample, optionally amplifying the nucleic acid, and analyzing the nucleic acid for a genetic variation in at least one mGluR network gene, and the results of the genetic test are obtained prior to a first administration of the activator.

40. 40. The method of claim 39, wherein the genetic testing comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, or all Tier 1 mGluR network genes.

41. 41. The method of claim 39 or claim 40, wherein the genetic testing comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 30, 50, 100, 150, 175, or all Tier 2 mGluR network genes.

42. 42. The method of any one of claims 39 to 41, wherein the genetic testing comprises analyzing the nucleic acid for CNVs or SNVs of at least 5, 10, 20, 50, 100, 200 300, 400, 500, or all Tier 3 mGluR network genes.

43. 43. The method of any one of claims 39 to 42, wherein the genetic test does not assess CNV of one or more of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

44. 44. The method of any one of claims 2, 4-24, or 27-43, wherein the subject has a genetic alteration, e.g., a CNV, in a Tier 1 or Tier 2 mGluR network gene, but does not have a genetic alteration, e.g., a CNV, in a Tier 3 mGluR network gene.

45. 45. The method of any one of claims 1 to 44, wherein treating ADHD in the subject comprises reducing at least one ADHD symptom in the subject, such as inattention, hyperactivity, or impulsivity.

46. The subject experiences the following changes in symptoms after at least 1, 2, 3, or 4 weeks of treatment with the activator: a. the subject has symptoms of anger difficulty being regulated, and the anger regulation symptoms are reduced; b. the subject has a symptom of disruptive behavior, and the symptom of disruptive behavior is reduced; c. the subject's CGI-I is reduced by at least 1 or at least 2; d. the subject has a CGI-I score of 1 or 2 after 1, 2, 3, or 4 weeks of treatment; e. the subject has a CGI-S score of 1 after 1, 2, 3, or 4 weeks of treatment; f. The subject's ADHD rating scale score is reduced by at least 25%, e.g., at least 30%, at least 35%, or at least 40%; g. the subject has a symptom of inattention and the symptom of inattention is reduced; h. the subject has a symptom of hyperactivity, and the symptom of hyperactivity is reduced; i. the subject has an impulsive symptom, and the impulsive symptom is reduced; j. the subject has symptoms of ODD, e.g., anger and irritability, argumentative and defiant behavior, and / or vindictiveness, and the ODD symptoms are reduced; k. the subject has symptoms of conduct disorder and the conduct disorder symptoms are reduced; l. the subject has symptoms of anxiety and the anxiety symptoms are reduced; m. the subject has symptoms of Tourette's syndrome, and the Tourette's syndrome symptoms are reduced; n. the subject has autistic symptoms and the autistic symptoms are reduced; and o. the subject has a movement disorder symptom, and the movement disorder symptom is reduced.

46. ​​The method of any one of claims 1 to 45, comprising one or more of:

47. 1. A method of treating 22q deletion and / or duplication syndrome in a subject, comprising administering to a subject having 22q deletion and / or duplication syndrome an effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator, thereby treating 22q deletion and / or duplication syndrome.

48. 48. The method of claim 47, wherein the subject has a genetic alteration in RANBP1, e.g., a point mutation, an insertion, a deletion, or a copy number variation (CNV).

49. 49. The method of claim 47 or 48, wherein the subject has a deletion or duplication in 22q11.

2.

50. 50. The method of claim 47, 48 or 49, wherein the subject has a genetic alteration in at least one mGluR network gene, e.g., a Tier 1, Tier 2 or Tier 3 gene.

51. 51. The method of any one of claims 47 to 50, wherein the subject has attention deficit hyperactivity disorder (ADHD).

52. 52. The method of any one of claims 47 to 51, wherein the subject is a child or adolescent subject, for example a subject between the ages of 5 and 17 years, between 8 and 17 years, between 5 and 12 years, between 5 and 8 years, between 8 and 12 years, or between 12 and 17 years.

53. 52. The method of any one of claims 47 to 51, wherein the subject is an adult subject.

54. 54. The method of any one of claims 47 to 53, wherein the non-selective mGluR activator is fasoracetam, e.g. fasoracetam monohydrate.

55. 55. The method of claim 54, wherein the fasoracetam is administered in a dose of 50-400 mg, such as 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, said dose being administered once, twice or three times daily.

56. 56. The method of claim 54 or claim 55, wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg or 400 mg twice daily, for example 100-200 mg twice daily.

57. The activator may be used in combination with a stimulant, such as methylphenidate, dexmethylphenidate, amphetamine, dextroamphetamine, or lisdexamfetamine, and / or in combination with a non-stimulant, such as atomoxetine, clonidine, or guanfacine, and / or in combination with an antidepressant, such as fluoxetine, escitalopram, bupropion, mirtazapine, amitriptyline, imipramine, venlafaxine, sertraline, paroxetine, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, or monoamine oxidase inhibitors, and / or in combination with an antianxiety drug, such as barbiturates, pregabalin, or benzodiazepines (chlordiazepoxide, clorazepate, 57. The method of any one of claims 47 to 56, wherein the agonist is administered in combination with a vasopressin-releasing agent (including, for example, diazepam, flurazepam, halazepam, prazepam, lorazepam, lormetazepam, oxazepam, temazepam, clonazepam, flunitrazepam, nimetazepam, nitrazepam, adinazolam, alprazolam, estazolam, triazolam, climazolam, loprazolam or midazolam), and / or in combination with an antipsychotic, such as, for example, aripiprazole or risperidone, and / or in combination with a beta-blocker, such as, for example, acebutolol, atenolol, betaxolol, bisoprolol, esmolol, nebivolol, metoprolol, cartelol, penbutolol, pindolol, carvedilol, labetalol, levobunolol, metipranolol, nadolol, propranolol, sotalol or timolol.

58. 58. The method of any one of claims 47 to 57, wherein the activator is administered in combination with a non-pharmacological therapy, such as brain stimulation, such as vagus nerve stimulation, repetitive transcranial magnetic stimulation, magnetoconvulsive therapy, and / or deep brain stimulation.

59. 59. The method of any one of claims 47 to 58, wherein the subject has at least one of oppositional defiant disorder (ODD), anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, mood disorder, phobia, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder.

60. 59. The method of any one of claims 47 to 58, wherein the subject does not have at least one of oppositional defiant disorder (ODD), anxiety disorder, conduct disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, mood disorder, phobia, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorder, or movement disorder.

61. 61. The method of claim 60, wherein the subject has ADHD but does not have at least one of ODD, conduct disorder, anxiety disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, mood disorder, phobia, obsessive-compulsive disorder (OCD), or movement disorder.

62. 62. The method of claim 60 or 61, wherein the subject does not have any of ODD, conduct disorder, anxiety disorder, Tourette's syndrome, autism, anger control difficulties, disruptive behavior, mood disorders, phobias, obsessive-compulsive disorder (OCD), self-injurious dermatopathy, developmental disorders, and movement disorders.

63. 63. The method of any one of claims 47 to 62, wherein the subject has ODD.

64. 64. The method of claim 63, wherein ODD in the subject is treated, e.g., by reducing symptoms of anger and irritability, argumentative and defiant behavior, and / or vindictiveness.

65. The method of any one of claims 47 to 64, wherein 22q deletion and / or duplication syndrome is diagnosed by a process comprising a genetic test to detect the presence or absence of a deletion or duplication at 22q11.2 and / or the presence or absence of a genetic alteration in RANBP1 in a sample from the subject, the method comprising obtaining the results of the genetic test prior to a first administration of the activator.

66. 66. The method of any one of claims 47 to 65, wherein the activator is administered in an amount effective to result in a Clinical Global Impression-Improvement (CGI-I) score of 1 or 2 after 4 weeks of treatment, and / or at least a 25%, such as at least a 30%, at least a 35%, or at least a 40% improvement in ADHD rating scale score after 4 weeks of treatment in a majority of subjects in at least one clinical trial.

67. 67. The method of any one of claims 47 to 66, wherein the 22q deletion and / or duplication syndrome is considered to be treated if at least one symptom of ADHD in the subject, such as impulsivity, hyperactivity or inattention, is improved.

68. 68. The method of any one of claims 1 to 67, wherein the subject does not have one or more CNVs and SNVs of GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7 or GRM8.

69. 1. A method for treating ADHD in a subject, comprising administering a therapeutically effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject having ADHD and at least one genetic alteration in an mGluR network gene, thereby treating the ADHD.

70. 1. A method for treating ODD in a subject, comprising administering a therapeutically effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject having ODD and at least one genetic alteration in an mGluR network gene, thereby treating the ODD.

71. A method for treating a subject having ADHD and ODD, comprising administering a therapeutically effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject having ADHD, ODD, and at least one genetic alteration in an mGluR network gene, thereby treating ADHD and ODD.

72. 1. A method for treating a subject having ADHD and autism, comprising administering a therapeutically effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject having ADHD, autism, and at least one genetic alteration in an mGluR network gene, thereby treating ADHD and autism.

73. 1. A method for treating a subject having ADHD and symptoms of anger control difficulties, comprising administering a therapeutically effective amount of a non-selective metabotropic glutamate receptor (mGluR) activator to a subject having ADHD, symptoms of anger control difficulties, and at least one genetic alteration in an mGluR network gene, thereby treating the ADHD and alleviating said symptoms of anger control difficulties.

74. 1. A method for treating a subject having ADHD and symptoms of disruptive behavior, comprising administering a therapeutically effective amount of a nonselective metabotropic glutamate receptor (mGluR) activator to a subject having ADHD, symptoms of disruptive behavior, and at least one genetic alteration in an mGluR network gene, thereby treating the ADHD and alleviating said symptoms of disruptive behavior.

75. 1. A method for treating a subject having ADHD and symptoms of a dyskinetic disorder, comprising administering a therapeutically effective amount of a nonselective metabotropic glutamate receptor (mGluR) activator to a subject having ADHD, symptoms of a dyskinetic disorder, and at least one genetic alteration in an mGluR network gene, thereby treating the ADHD and alleviating the symptoms of the dyskinetic disorder.

76. 76. The method of any one of claims 69 to 75, wherein the non-selective mGluR activator is fasoracetam, e.g. fasoracetam monohydrate.

77. 77. The method of claim 76, wherein the fasoracetam is administered in a dose of 50-400 mg, such as 100-400 mg, or 100-200 mg, or 200-400 mg, or 100 mg, or 200 mg, or 300 mg, or 400 mg, said dose being administered once, twice or three times daily.

78. 77. The method of claim 76, wherein the fasoracetam is administered at a dose of 100 mg, 200 mg, 300 mg or 400 mg twice daily, such as 100-200 mg twice daily, or 200-400 mg twice daily.

79. 76. The method of any one of claims 69 to 75, wherein the genetic alteration is a copy number variation (CNV).

Citation Information

Patent Citations

  • Treatment of tics, tremors, and related disorders

    JP2004523557A

  • The association of low-frequency recurrent genetic mutations with attention-deficit hyperactivity disorder and their use for diagnosis and treatment, by Joseph Gressner, Josephine Elia, and Hacon Haconalson. This application claims priority to U.S. Provisional Applications 61 / 376,498 and 61 / 466,657, filed on 24 August 2010 and 23 March 2011, respectively, the entire contents of which are incorporated herein by reference as if they were fully described.

    JP2013535985A

  • Antidepressant

    WO1995003801A1